Posted on

Cbd oil replace ropinerol for parkinson

Marijuana Compounds: A Nonconventional Approach to Parkinson’s Disease Therapy

This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Parkinson’s disease (PD), a neurodegenerative disorder, is the second most common neurological illness in United States. Neurologically, it is characterized by the selective degeneration of a unique population of cells, the nigrostriatal dopamine neurons. The current treatment is symptomatic and mainly involves replacement of dopamine deficiency. This therapy improves only motor symptoms of Parkinson’s disease and is associated with a number of adverse effects including dyskinesia. Therefore, there is unmet need for more comprehensive approach in the management of PD. Cannabis and related compounds have created significant research interest as a promising therapy in neurodegenerative and movement disorders. In this review we examine the potential benefits of medical marijuana and related compounds in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease. The potential for cannabis to enhance the quality of life of Parkinson’s patients is explored.

1. Introduction

Marijuana, the crude product (dried flowers, stems, seeds, and leaves) derived from the cannabis sativa plant, consists of more than 85 phytocannabinoids [1, 2]. The term phytocannabinoids is used to differentiate these plant-derived cannabinoids from the synthetic cannabinoids and the structurally different endogenous cannabinoids (endocannabinoids). Among the phytocannabinoids, Cannabidiol (CBD) and Δ9-Tetrahydrocannabinol (Δ9-THC, THC) are the major constituents of marijuana [3]. Δ9-THC is a psychoactive agent with analgesic and muscle relaxant property [3, 4]. While CBD is a nonpsychoactive compound and has been shown to have hypnotic, anxiolytic, antipsychotic, antioxidant, and neuroprotective effects [5], THC is a partial agonist at the cannabinoid receptor 1 (CB1) and receptor 2 (CB2). Unlike Δ9-THC, CBD has antagonistic/inverse agonistic property at CB1 receptor and appears to modulate Δ9-THC-associated side effects including anxiety, tachycardia, and hunger [3]. CBD also appears to potentiate the effect of endocannabinoids by inhibiting their inactivation, thereby alleviating psychotic symptom [6].

Despite the placement of marijuana in the schedule 1 category under the US Federal Controlled Substance Act [7] and the US Federal Government’s continued opposition on its legalization, 24 states and Washington DC have enacted laws allowing marijuana to treat certain medical conditions [8]. The range and types of disease conditions for which medical marijuana have been approved vary from state to state. The most common disease conditions approved by the states include cancer, HIV/AIDS, glaucoma, chronic and/or severe pain, seizure/epilepsy, cachexia, and multiple sclerosis. Moreover, two cannabinoids (dronabinol and nabilone) have been approved by the FDA for clinical use. The synthetically produced Δ9-THC, dronabinol (Marinol®), is a schedule III drug, which is indicated in the treatment of chemotherapy-induced nausea and emesis as well as anorexia associated with weight loss in AIDS patients. A synthetic cannabinoid, nabilone (Cesamet®), is a schedule II drug that is indicated for the treatment of nausea and vomiting associated with cancer chemotherapy. Another cannabinoid, Cannabidiol (Epidiolex®), is in a clinical trial for the treatment of drug- resistant epilepsy in children [9]. A phytocannabinoid preparation, nabiximols (Sativex®), has been approved for the treatment of spasticity due to multiple sclerosis in a number of countries outside the United States. Nabiximols is an extract of Cannabis sativa L that consists of mainly THC and CBD [10, 11].

Although recent studies have provided strong evidence for the therapeutic benefit of medical marijuana [12–16], increasing access to cannabis and/or cannabinoids can result in side effects such as addiction, respiratory illness, and decline in cognitive processing. Cannabis use has been indicated as a potential cause, aggravator, or masker of major psychiatric symptoms, including psychotic, depressive, and anxiety disorders, particularly in young people [17–19]. Other negative effects include working memory deficits, reduced attention and processing speed, anhedonia, abnormal social behavior, and susceptibility to mood and anxiety disorders [20, 21]. While adult users seem comparatively resistant to cannabis-induced behavioral and brain morphologic changes, the individuals who start using cannabis during their early teens can have more severe and more long-lasting effects [22].

The target of medical marijuana and its constituents is the endocannabinoid system, which is involved in the modulation of a number of physiological functions. The endocannabinoid system includes the endocannabinoids, the cannabinoid receptors, and the enzymes involved in the biosynthesis and inactivation of the endocannabinoids [23] The cannabinoid receptors are mainly expressed in the central nervous system and the immune system, but they have also been identified in a number of other parts of the body including the cardiovascular system, the peripheral nervous system, the reproductive system, and the gastrointestinal tract. Due to its wide distribution and effects on a range of biological process, the cannabinoid system has become an attractive target for the development of drugs that can potentially be used for the treatment of a number of pathological conditions including mood disorders and movement disorders such as PD [24]. Components of the endocannabinoid system are abundant in the striatum and other parts of the basal ganglia and play a crucial role in modulating dopamine activity and motor functions [25–27].

Parkinson’s disease (PD) is the second most common neurodegenerative disorder following Alzheimer’s disease and the 14th leading cause of death in all age groups in the United States [28]. The prevalence of PD increases with age and is shown to be higher in males than females in some age groups [29]. The number of people with PD is projected at approximately 9 million by 2030 in the 15 most populous countries in the world [30, 31]. Neurologically PD is characterized by the destruction of dopaminergic cells in the pars compacta region of the substantia nigra in the midbrain, resulting in dopamine deficiency in the nerve terminals of the striatum in the forebrain [32]. These changes cause impairments not just to the motor system but also to the cognitive and neuropsychological systems [33]. The nigrostriatal pathway is one of the dopamine pathways in the brain that regulates movement. The exact cause for the loss of neuronal cells is unknown, and the trigger of dopaminergic degeneration seems to be multifactorial including environmental factors and genetic susceptibilities [34–36]. Clinically, PD is characterized by resting tremor, muscle rigidity, bradykinesia, and postural instability [32, 34, 37, 38] and it is also associated with a number of nonmotor symptoms including depression, anxiety, constipation, orthostatic hypotension, fatigue, and sleep disorders, as well as, in advanced disease, dementia [39–44]. Although dopamine deficiency accounts for the major motor symptoms of the disease, loss of noradrenergic and serotoninergic nerve terminals in the limbic system may account for several of the nonmotor features seen in Parkinson’s disease [45, 46].

Current therapy involves treatment of motor symptoms of PD through replacement of dopamine deficiency [47]. This includes (1) enhancement of the synthesis of brain dopamine by administration of levodopa, a dopamine precursor, (2) direct stimulation of dopamine receptors, (3) decreasing dopamine catabolism, and (4) stimulation of dopamine release and inhibition of dopamine reuptake from presynaptic sites. Another therapy involves restoring the normal balance of cholinergic and dopaminergic actions on the basal ganglia using anticholinergic drugs [47–49].

However these drugs treat only motor symptoms of Parkinson’s disease and are associated with a number of adverse effects. Long-term use of levodopa, the mainstay therapy for PD, is associated with motor fluctuations [50] and levodopa-induced dyskinesia [51–53]. The monoamine oxidase B (MAO-B) inhibitors (selegiline and rasagiline) as well as inhibitors of catechol-o-methyltransferase, COMT (tolcapone and entacapone), are used mostly to reduce the motor fluctuations associated with levodopa therapy due to their levodopa-sparing effect [54–59]. Several dopamine agonists including pramipexole, ropinirole, rotigotine, and apomorphine are used as monotherapy in early stage of Parkinson disease or as adjunctive therapy with levodopa in patients with advanced PD in order to reduce motor fluctuations [56, 60–64]. In addition to their limited efficacy on motor symptoms and their adverse effects, drugs that are currently used for the treatment of PD do not have an effect on disease progression. Therefore, there is an urgent need for the development of safer drugs that treat both the motor and nonmotor symptoms of PD as well as drugs that slow the progression of the disease.

Medical marijuana has been demonstrated to improve motor symptoms including tremor, rigidity, and bradykinesia as well as nonmotor symptoms such as pain and sleep disorders of PD in observational studies [65]. Survey of PD patients in Colorado, USA, also indicated the beneficial effects of marijuana in alleviating nonmotor symptoms of PD [66]. Cannabidiol (CBD), one of the major constituents of marijuana, has been shown to be effective in the treatment of psychosis and sleep disorders in PD patients [67–69]. Another phytocannabinoid, Δ9-tetrahydrocannabivarin (Δ9-THCV, THCV), was studied in animal disease model of PD and found to have neuroprotective and symptom-relieving effects [70]. Therefore, marijuana may provide an alternative or add-on therapy for Parkinson’s disease. In addition, Parkinson’s disease has been listed as one of the disease conditions for which medical marijuana is allowed in Connecticut, Illinois, Massachusetts, New Hampshire, New Mexico, and New York. However, it may also be covered under chronic illnesses in several other states.

In this review we seek to investigate any scientific evidence that indicates the potential use of marijuana and/or its components for the treatment of Parkinson’s disease. The review aims to (i) examine briefly current treatment and the unmet need of PD therapy, (ii) assess the role of the cannabinoid system in the modulation of movement and neuroprotection, (iii) look at the mechanism of action of marihuana constituents in the modulation of movement and PD-associated disorders, (iv) assess other beneficial effects of marihuana that contribute to the amelioration of PD, and (v) gather scientific evidence on the clinical benefit of marijuana and/or its constituents in PD patients.

2. Marijuana and Its Influence on the Endocannabinoid System

Cannabis has been used to treat disease since ancient times. Marijuana is derived from the Cannabis sativa L. plant. Marijuana contains the active chemicals known as cannabinoids. At least 85 cannabinoids have been identified as unique compounds in Cannabis [1]. The therapeutic potential of many of these ligands still remains largely unexplored prompting a need for further research. The chemicals responsible for the medicinal effects of marijuana are D9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) [71, 72]. THC is the major psychoactive ingredient, acting primarily upon the central nervous system where it affects brain function. CBD is the major nonpsychoactive ingredient in cannabis and produces neuroprotective and anti-inflammatory effects [73]. Both compounds, TCH and CBD, have anticonvulsant properties [74]. Cannabinoids have also potential to alleviate motor disorders by reducing motor impairments and neuron degeneration [75]. In addition, cannabinoids have been shown to be effective in preclinical studies involving excitotoxicity, oxidative stress, neuroinflammation, and motor complications associated with PD [76].

Some cannabinoids (endocannabinoids or ECBs) are found in the body. Initially, ECBs were discovered in the brain and subsequently in the periphery in humans and animals. Endocannabinoids are produced by cultured neurons [77], microglia, and astrocytes [78]. ECBs interact with the endocannabinoid system and aid in regulation of memory, pleasure, concentration, thinking, movement and coordination, sensory and time perception, appetite, and pain [24, 79, 80]. The ECBs activate two guanine nucleotide-binding protein- (G-protein-) coupled cell membrane receptors, consequently named the cannabinoid type 1 (CB1) and type 2 (CB2) receptors [81]. CB1 receptors are located primarily in the central and peripheral neurons and CB2 receptors are predominantly found in immune cells [82]. CB1 receptors are important mediators in signaling pathways and have been identified on both glutamatergic and gammaaminobutyric (GABA) neurons [83]. It is believed that one important role of the neuronal CB1 component is to modulate neurotransmitter release in a manner that maintains homeostasis by preventing the development of excessive neuronal activity in the central nervous system [82]. Animal models illustrate that activation of the CB1 receptor by their endogenous ligands can result in prominent neuroprotective effects and may prevent epileptic seizures [84]. Other studies suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L-DOPA-induced dyskinesias [85]. CB2 receptors are closely related to CB1 and are mainly expressed on T cells of the immune system, on macrophages and B cells, and in hematopoietic cells [86]. They are also expressed on peripheral nerve terminals where these receptors play a role in antinociception and the relief of pain [87]. In the brain, CB2 receptors are mainly expressed by microglial cells, where their role remains unclear [88].

The major identified ECBs are arachidonoyl ethanolamide (anandamide, AEA), 2-arachidonoyl glycerol (2-AG), O-arachidonoyl ethanolamine (virodhamine), and 2-arachidonoyl glyceryl ether (noladin ether) [89]. Both AEA and 2-AG are specific ligands of CB1 and CB2 receptors. Besides having activity on CB1 and CB2 receptors, AEA also has full agonistic activity at TRPV1 receptor [90]. AEA is localized in the brain and periphery [91]. In the brain AEA shows high distribution in the hippocampus, thalamus, striatum, and brainstem and to a lesser extent in the cerebral cortex and cerebellum [92]. Lower concentrations of AEA are found in human serum, plasma, and cerebrospinal fluid [93]. Similarly, 2-AG is observed in both the brain and periphery, although its concentration is almost 150 times higher in brain compared to that of AEA [92, 94, 95]. 2-AG has greater potency, stability, and agonistic activity at CB1 and CB2 receptors compared to that of AEA [96, 97]. Two prominent areas involved in the control of movement, such as the globus pallidus and the substantia nigra, contain not only the highest densities of CB1 receptors [88], but also the highest levels of ECBs, especially AEA [98, 99]. Tissue levels of AEA are regulated by fatty acid amide hydrolase (FAAH) [100]. It has also been shown that the basal ganglia contain the precursor of AEA [98, 99], supporting the theory of in situ synthesis for this compound. Studies have demonstrated that AEA synthesis is regulated by dopaminergic D2 receptors in the striatum, suggesting that the endocannabinoid system acts as an inhibitory feedback mechanism countering the dopamine-induced facilitation of motor activity [101].

Marijuana compound THC is CB1 and CB2 receptor partial agonist [82]. Due to the structural similarity of natural cannabinoid THC to the endogenous cannabinoid AEA, many therapeutic advantages of THC have been identified, such as lowering ocular pressure, inhibiting smooth muscle contractions, and increasing appetite [102]. When smoked, THC is rapidly absorbed from the lungs into the bloodstream and has an effect on the cannabinoid receptors. The central nervous system and specific areas of the brain contain the highest concentration of cannabinoid receptors. Therefore, cannabis or THC administration can create an overexcitation of the system that results in altered perceptions, pleasure, and mood [103].

Unlike THC, CBD has little affinity for CB1 and CB2 receptors but acts as an indirect antagonist of cannabinoid agonists. While this should cause CBD to reduce the effects of THC, it may potentiate THC’s effects by increasing CB1 receptor density or through another CB1-related mechanism [73]. CBD is also an inverse agonist of CB2 receptors. CBD can counteract some of the functional consequences of CB1 activation in the brain, possibly by indirect enhancement of adenosine A1 receptors activity through equilibrative nucleoside transporter (ENT) inhibition [73]. CBD helps to augment some of THC’s beneficial effects, as it reduces the psychoactivity of THC, enhances its tolerability, and widens THC’s therapeutic window [104].

Other cannabinoids can also contribute to the cannabis medicinal effects. Studies in experimental models and humans have suggested anti-inflammatory, neuroprotective, anxiolytic, and antipsychotic properties of chemicals extracted from marijuana [6, 15, 82, 105, 106].

3. Cannabinoids and Parkinson’s Disease

3.1. Changes in the Cannabinoid System in Parkinson’s Disease

Recent data from several studies indicate the important role of the endocannabinoid system in Parkinson’s disease. The components of the endocannabinoid system are highly expressed in the neural circuit of basal ganglia, which is part of a complex neuronal system. This neuronal system coordinates activities from different cortical regions that directly or indirectly participate in the control of movement [107, 108]. In the basal ganglia, the endocannabinoid system bidirectionally interacts with dopaminergic, glutamatergic, and GABAergic signaling systems [109]. Endocannabinoids play a dominant role in controlling transmission at synapses between cortical and striatal neurons, in mediating the induction of a particular form of synaptic plasticity, and in modulating basal ganglia activity and motor functions [110]. The progressive loss of dopaminergic neurons that occurs in PD leads to lower striatal levels of dopamine. These low levels of dopamine result in the alteration of the equilibrium between the direct and the indirect basal ganglia pathways and ECB signaling [111].

The cannabinoid signaling system mentioned above experiences a biphasic pattern of changes during the progression of PD [112]. Early and presymptomatic PD stages, characterized by neuronal malfunction with little evidence of neuronal death, are associated with desensitization/downregulation of CB1 receptors and aggravation of various cytotoxic insults such as excitotoxicity, oxidative stress, and glial activation [113]. However, intermediate and advanced stages of PD, characterized by a deep nigral degeneration and manifestation of major Parkinsonian symptoms, are associated with upregulatory responses of CB1 receptors and the endocannabinoid ligands [113]. This could explain the potential of CB1 receptor ligands in alleviating common PD symptoms.

In the brain, CB1 receptors are expressed by GABAergic neurons innervating the external and internal segments of the globus pallidus and the substantia nigra [114–116]. CB1 receptors are also present in the corticostriatal glutamatergic terminals and in the excitatory projections from the subthalamic nucleus to the internal segment of the globus pallidus and the substantia nigra [114–116]. Within the striatum, CB1 receptors are expressed in parvalbumin immune-reactive interneurons, cholinergic interneurons, and nitric oxide synthase-positive neurons [117, 118]. Animal models of Parkinson’s disease show an increase in the density of CB1 receptors, levels of endogenous ligands, and CB1 receptor binding in the basal ganglia [119–122]. Endogenous cannabinoids activate CB1 receptors on presynaptic axons and reduce neurotransmitter and glutamate release, working as retrograde synaptic messengers released from postsynaptic neurons [123]. Similarly, activation of CB1 receptors inhibits both glutamate release from substantia nigra afferents and GABA release from striatal afferents. At the same time, activation of presynaptic CB1 receptors in the external segments of the globus pallidus can increase local GABA levels by reducing GABA reuptake from striatal afferents to the nucleus and decrease GABA release from striatal afferents of the substantia nigra [114, 116, 118]. Based on these evidences, it is thought that the function of the basal ganglia neuronal system is controlled by ECB. The presence of endocannabinoid systems in different neural structures and their interaction with dopaminergic, glutamatergic, and GABAergic neurotransmitter signaling systems make the components of endocannabinoid system ideal targets for a novel nondopaminergic treatment of PD.

Endocannabinoid signaling is also bidirectionally linked to dopaminergic signaling within the basal ganglia [118]. The CB1, D1, and D2 dopamine receptors are localized in the striatum [114, 115]. In animal models, CB1 and D2 dopamine receptors share a common pool of G proteins, suggesting the link of their signal transduction mechanisms [124, 125]. In addition, D2 receptor stimulation resulted in release of ECBs in the striatum [101]. However, stimulation of CB1 receptors completely inhibited D1-dopamine receptor mediated activation of adenylyl cyclase and decreased GABA release from striatal afferents of dopaminergic neurons of the substantia nigra resulting in an increased firing of these cells [114–116].

Another receptor involved in control of movement is transient receptor potential vanilloid type 1 (TRPV1), which is expressed in sensory neurons and basal ganglia circuitry of dopaminergic neurons [126, 127]. TRPV1 receptors are molecular integrators of nociceptive stimuli activated by endovanilloids [128]. TRPV1 also interacts with ECB. In particular, anandamide is one of the major endogenous activators of TRPV1 [129–131]. Studies have revealed that motor behavior can be suppressed by the activation of vanilloid receptors [98, 99], suggesting that TRPV1 receptors might play a role in the control of motor function.

3.2. Preclinical Data on the Endocannabinoid System as a Target for Parkinson’s Disease Therapy

The association of cannabinoids with regulation of motor functions is well established [132–135]. The effect of the cannabinoids on motor activity depends on the impact of the endocannabinoid system on the dopaminergic, glutamatergic, and GABAergic signaling systems throughout the basal ganglia [112, 136]. The high density of cannabinoid, dopamine, and vanilloid-like receptors coupled with ECBs within the basal ganglia and cerebellum suggests a potential therapeutic role for the cannabinoids in the control of voluntary movement and in movement disorders such as Parkinson’s disease [98, 99, 121, 137]. Additional indications of an important role of the endocannabinoid system in the control of movement involve an inhibitory action of cannabinoids through fine tuning of various classical neurotransmitters activity [138], prominent changes in transmission of ECBs in the basal ganglia [139], and alteration of the CB1 binding as well as CB1 availability in the substantia nigra [85, 112, 119, 120, 140, 141]. These data support the idea that cannabinoid- based compounds act on vital pathways of endocannabinoid transmission and therefore might be of therapeutic interest due to their potential to diminish motor symptoms in extrapyramidal disorders such as Parkinson’s disease [27, 76, 142].

Research with cannabinoid agonists and antagonists demonstrates that the cannabinoids can modulate motor activity and produce alterations in corresponding molecular correlates [129, 143–145]. It has been widely reported that synthetic, plant-derived, or endogenous cannabinoid agonists exert a powerful motor inhibition in laboratory species [129, 144, 146–149]. This hypokinetic effect was shown to be mediated by the activation of CB1 receptors in neurons of the basal ganglia circuitry [88, 137, 141, 150–152]. Stimulation of the CB1 receptor by a synthetic cannabinoid HU-210 decreased spontaneous glutamatergic activity and reduced the rotations induced by levodopa/carbidopa by 34% in PD rats [153, 154]. Administration of CB1 receptor agonists THC and two synthetic cannabinoids WIN 55,212-2 and CP 55,940 increased extracellular dopamine concentrations in rats [152, 155, 156]. WIN 55,212-2 and CP 55,940 also weakened contralateral rotations induced by a selective D1/D5 receptor partial agonist > SKF38393 without developing catalepsy in PD rats [148]. In a gender study THC produced an increase in tyrosine hydroxylase activity in parkin-null male mice (a model of early stages of PD) and caused a motor inhibition that was significantly greater compared to wild-type animals [122]. Treatment with THC inhibited motor activity and produced catalepsy in rats [109, 144, 146, 147] and caused antinociception and ring immobility in mice [157]. In other studies THC diminished the motor inhibition caused by 6-hydroxydopamine [70] and potentiated the hypokinetic effect of reserpine in rats more than 20-fold [135]. However, in a primate model of Parkinson’s disease THC did not affect locomotor activity but increased bradykinesia [125].

Administration of WIN 55,212-2 increased stimulation of GTPγ S binding in the caudate nucleus, putamen, globus pallidus, and substantia nigra of marmosets, indicating an effective activation of CB1 signaling mechanisms [119, 120]. WIN 55,212-2 produced a dose-dependent reduction of the spontaneous motor activity and catalepsy in mutant Syrian hamsters, increased antidystonic efficacy of benzodiazepines [158], and significantly reduced the antikinetic effects of quinpirole in the reserpine-treated rats [159]. Treatment with WIN 55,212-2 also reduced levodopa-induced dyskinesias, attenuated axial, limb, and severe orolingual abnormal involuntary movements in 6-hyroxydopamine- (6-OHDA-) lesioned rats [160–163]. An endogenous cannabinoid agonist oleoylethanolamide (OAE) produced reduction in dyskinetic contralateral rotations correlated with reduction of molecular associates of L-DOPA-induced dyskinesia: reduced FosB striatal overexpression and phosphoacetylation of hystone 3 [164]. Another synthetic agonist levonantradol decreased general and locomotor activity and increased bradykinesia in a primate model of Parkinson’s disease [125]. Nabilone, a synthetic cannabinoid agonist, coadministered with levodopa significantly decreased total dyskinesia compared with levodopa alone treatment and increased the duration of antiparkinsonian action of levodopa by 76% in PD marmosets [165, 166].

Cannabinoid agonist anandamide (AEA) and its synthetic analog methanandamide increased the extracellular dopamine levels in the nucleus accumbens shell of rats by the activation of the mesolimbic dopaminergic system [167]. This dopamine increase was inhibited by the cannabinoid CB1 receptor antagonist rimonabant [167]. However, recent discoveries indicate that AEA is also able to activate vanilloid VR(1) receptors and that the activation of these receptors might also be responsible for changes in nigrostriatal dopaminergic activity and anandamide-induced hypokinesia [168–170]. AEA produced a tonic facilitation of glutamate release in the substantia nigra via stimulation of VR1 receptors, indicating the involvement of this receptor in motor and cognitive functions of the dopaminergic system [171]. Preclinical data have shown that AEA decreased the activity of nigrostriatal dopaminergic neurons and produced hypokinesia that was completely reversed by an antagonist of vanilloid-like receptors, capsazepine [129]. Additional studies have demonstrated that AEA inhibited ambulation and stereotypic behavior, increased inactivity, and occluded the effects of an agonist of vanilloid VR1 receptors, livanil, on locomotion in mice, suggesting a common mechanism of action for the two compounds [170]. Treatment with anandamide lowered motor activity with the maximal inhibition by approximately 85% and produced hypothermia and analgesia in mice, increased the inactivity time, and markedly decreased the ambulation and the frequency of spontaneous non-ambulatory activities in rats [146, 147, 172, 173]. Moreover, AEA produced a decrease in spontaneous motor activity in laboratory animals similar to the reported actions of THC [129, 145, 153, 170]. The hypokinetic actions of AEA were boosted by coadministration with a selective inhibitor of endocannabinoid uptake N-(3-furylmethyl) eicosa-5,8,11,14-tetraenamide, UCM707 [174].

Tissue concentrations of endocannabinoids are important for producing motor effects. Levels and activities of AEA and 2-AG can be manipulated by inhibition of FAAH enzyme, the action of which is reduced in experimental models of PD [153, 175]. Animal studies have shown that the FAAH enzyme inhibitor [3-(3-carbamoylphenyl) phenyl] N- cyclohexylcarbamate (URB597) magnified and prolonged a rapid, brief dopamine increase that was produced by AEA [167]. Additional studies have confirmed that FAAH inhibition remarkably increases AEA tissue levels but reduces 2-AG levels [176, 177]. To determine whether FAAH inhibition has beneficial impact on PD symptoms the effect of the FAAH inhibitor, URB597, was studied in MPTP- lesioned marmosets. Treatment with URB597 increased plasma levels of AEA, did not modify the antiparkinsonian actions of L-DOPA, and reduced the magnitude of hyperactivity to levels equivalent to those seen in normal animals [178]. In PD mice URB597 prevented induced motor impairment [179]. Moreover, other FAAH inhibitors, JNJ1661010 and TCF2, also have anticataleptic properties [179]. These results reveal that FAAH inhibition may represent a new strategy for treatment of PD.

Overall, these results indicate that endogenous or exogenous cannabinoid agonists activate the dopaminergic system and play a very important role in modulation of motor behavior [180]. In addition to the effects on movement activity, cannabinoid agonists have demonstrated neuroprotective properties, suggesting that the cannabinoids have a promising pharmacological profile for not only improving Parkinsonian symptoms but also delaying PD progression [70, 85, 181–183].

The CB1 receptor antagonists can also influence movement syndromes of Parkinson’s disease suggesting that modulation of the CB1 signaling system might be valuable in treatment of motor disorders. In a study with PD rats rimonabant (SR141716A), a selective antagonist of CB1 receptors has shown the potential to act as an antihypokinetic agent by enhancing glutamate release from excitatory afferents to the striatum [184]. Moreover, SR141716A prevented the effects of THC on dopamine release [156, 167] and also increased the locomotor activity in mice and rats preexposed to THC [170, 185]. SR141716A produced a 71% increase in motor activity in MPTP-lesioned marmosets with LID [136]. Coadministration of SR141716A with levodopa resulted in significantly less dyskinesia than administration of levodopa alone [136, 160]. SR141716A also reversed effect of the cannabinoid agonist WIN 55,212-2 and increased the locomotor activity in 6-OHDA-lesioned animals [159, 163]. Coadministration of SR141716A with a selective D2/D3 receptor agonist quinpirole reduced levels of AEA and 2AG by sevenfold in the globus pallidus, boosted the locomotive effects of quinpirole, and produced restoration of locomotion in animal models of Parkinson’s disease [98, 99, 101, 136, 186]. In parkin-null mice SR141716A produced a decrease in tyrosine hydroxylase activity in the caudate–putamen and as result formed a hyperkinetic response [122]. However, SR141716A did not alleviate the motor deficits in a primate model of Parkinson’s disease [125].

Another CB1 receptor antagonist AM251 and SR141716A produced antiparkinsonian effects in rats with very severe nigral degeneration (>95% cell loss) [187]. Local administration of these antagonists into denervated striatum, globus pallidus, and subthalamic nucleus reduced motor asymmetry in Parkinsonian rats [187, 188], which was inhibited by CB1 receptor agonist AM404 [187]. Another CB1 antagonist CE-178253 produced a 30% increase in motor behavior responses to L-DOPA in MPTP-treated rhesus monkeys but did not modify levodopa-induced dyskinesias [189]. THCV caused changes in glutamatergic transmission and attenuated the motor inhibition in PD rats [70]. Overall, these findings suggest that cannabinoid CB1 antagonists might be therapeutically effective in the control of Parkinson’s disease and levodopa-induced dyskinesia [114, 190].

The activation of CB2 receptors might also contribute to some extent to the potential of cannabinoids in PD [191]. THCV, which is not only a CB1 antagonist but also a CB2 partial agonist, reduced the loss of tyrosine hydroxylase-positive neurons in the substantia nigra with preservation of these neurons in CB2 receptor-deficient mice [70]. CBD has also reduced the loss of tyrosine hydroxylase-positive neurons in the substantia nigra of PD rats. Both compounds, THCV and CBD, have acted via neuroprotective and antioxidant mechanisms [70, 182, 191]. CBD has also demonstrated significant effects in preclinical models of neurodegenerative disorders in combination with other cannabinoids [15, 70, 192]. CB2 receptor agonists display a promising pharmacological profile for delaying disease progression.

The cannabinoid pharmacologic manipulation represents a promising therapy to alleviate movement disorders and levodopa-induced dyskinesias. Thus, CB1 antagonists appear to have antiparkinsonian effects, while cannabinoid receptor agonists may be useful in the treatment of motor complications in Parkinson’s disease.

3.3. Effect of Cannabinoids on Patients with Movement Disorders

Cannabis and related compounds have created significant research interest as a promising therapy in neurodegenerative and movement disorders. The successful use of tincture of Cannabis indica in treating PD was first described in Europe by Gowers [193]. Despite the lack of controlled studies, there is evidence that cannabinoids are of therapeutic value in the treatment of tics in Tourette syndrome, some forms of tremor and dystonia, chorea in Huntington’s disease, the reduction of levodopa-induced dyskinesia in Parkinson’s disease, and Parkinsonian syndromes [194–201].

A study with smoked cannabis queried 339 PD patients indicated that marijuana produced significant improvement of general PD symptoms in 46% of the patients; 31 % of them reported improvement in resting tremor, 38% reported relief from rigidity, 45% defined reduced bradykinesia, and 14% of the patients reported alleviated dyskinesias [202]. High urine concentration (>50 ng/ml) of the THC primary active metabolite, 11-HO-THC, was associated with relief from PD symptoms [202]. The dose and frequency of the cannabis administrations were important in relieving PD symptoms. Smoked cannabis also produced a statistically significant improvement in tremor, rigidity, and bradykinesia as well as improvement in sleep and pain scores in 22 PD patients [65]. In another study, smoked cannabis was responsible for a significant improvement in the mean total motor Unified Parkinson’s Disease Rating Scale (UPDRS) score, tremor, rigidity, and bradykinesia in 17 patients with PD [203]. One dose of smoked marijuana provided symptoms relief for up to 3 hours [203]. Moreover, both studies reported significant improvement of nonmotor symptoms of PD, such as pain and sleep [65, 203]. However, smoked marijuana did not reduce Parkinsonian symptoms in 5 patients with idiopathic Parkinson’s disease and severe tremor [204]. A clinical trial in 19 PD and 6 patients with levodopa-induced dyskinesia demonstrated that oral cannabis extract was ineffective for alleviating parkinsonism or dyskinesia [205].

Few studies have evaluated the effects of CBD on PD symptoms. In a pilot study CBD lowered total UPDRS scores and significantly reduced psychotic symptoms in 6 PD patients with psychosis [67]. In another study CBD administration produced no improvement in measures of motor and general symptoms in 21 PD patients [68, 69]. However, the group treated with CBD had significantly different mean total scores in the Parkinson’s Disease Questionnaire, 39 compared to the placebo group [68, 69]. Oral CBD improved dyskinesia by up to 30% without a significant worsening of the parkinsonism in PD patients [206]. CBD withdrawal caused severe generalized dystonia [206].

Clinical studies have been conducted to evaluate the effect of a synthetic cannabinoid nabilone. Oral nabilone significantly reduced dyskinesia without aggravating parkinsonism in seven PD patients with severe L-DOPA-induced dyskinesia [207]. In another study, nabilone produced a 22% reduction in levodopa-induced dyskinesia in PD patients [208]. Nabilone showed efficacy not only against LID but also against bradykinesia in PD patients [209]. Some other cannabinoid related compounds such as > CE178253, OEA, and HU-210 have also been reported to be efficacious against L-DOPA-induced dyskinesia and bradykinesia in PD [199, 209]. However, SR 141716 did not improve Parkinsonian motor disability in PD patients [210]. The American Academy of Neurology (AAN) review deemed marijuana “probably ineffective” for treating L-DOPA-induced dyskinesia [211]. These conflicting results indicate the need for more research in this area.

Several clinical studies have been performed to evaluate the effect of marijuana on dystonia. Inhaled cannabis has provided a marked reduction in dystonia and complete pain relief in patients with right hemiplegic painful dystonia. Moreover, the patients have been able to completely discontinue opioid use [212]. Smoked cannabis also improved idiopathic dystonia and generalized dystonia due to Wilson’s disease [213, 214]. In a preliminary study, administration of CBD resulted in a 50% improvement in spasm severity and frequency in a patient with blepharospasm-oromandibular dystonia [215] and amelioration of the dystonic movements within 2-3 hours in patients with dystonic movement disorders [201]. CBD also improved dystonia by 20–50% in dystonic patients and stopped tremor and hypokinesia in 2 patients with Parkinson’s disease [200]. Another cannabis compound, THC, produced a reduction of abnormal movement patterns in a 14-year-old girl with marked dystonia [216] and decreased intensity of myoclonic movements in a 13-year-old boy with athetosis and myoclonic movements [216]. In contrast to these findings, one study found no significant reduction in dystonia following treatment with nabilone [165, 166].

Studies have looked at the potential benefits of medical marijuana and cannabinoids for the treatment of Huntington’s disease (HD). Nabilone versus placebo showed a treatment difference of 0.86 for total motor score; 1.68 for chorea; 3.57 for Unified Huntington’s Disease Rating Scale (UHDRS) cognition; 4.01 for UHDRS behavior; and 6.43 for the neuropsychiatric inventory in HD patients [217]. However, in previous study nabilone was found to increase choreatic movements in patients with HD [197, 198]. AAN guideline examining the efficacy of marijuana for treating chorea in HD stated nabilone can be used for modest decreases in HD chorea [218]. Available data regarding the effect of CBD on HD symptoms are inconsistent. CBD produced improvement (20–40%) in the choreic movements in HD patients [219]. However, a latter study did not confirm the earlier finding [220]. A comparison of the effects of CBD and placebo on chorea severity in neuroleptic-free HD patients indicated no significant or clinically important differences [220].

Few studies have indicated that marijuana and THC can reduce tics and associated behavioral disorders in patients with Tourette’s syndrome (TS) [221]. Cannabis inhalations produced a significant amelioration of TS symptoms [222]. Following marijuana administration 82% of TS patients (N = 64) reported a reduction, or complete remission of motor and vocal tics, and an amelioration of premonitory urges and obsessive-compulsive symptoms (OCB) [199]. Smoked marijuana also eliminated TS symptoms in one case study [223]. Administration of THC to a boy with TS improved tics and enhanced short-interval intracortical inhibition and the prolongation of the cortical silent period [224]. TCH significantly reduced tics and improve driving ability in a Tourette’s patient [225]. Treatment with THC lowered the mean C1 specific over nonspecific binding ratio (V 3′′) from 0.30 to 0.25 in six TS patients, although the difference was not significant. However V 3′′ clearly declined in a patient with a marked clinical response [226]. To date, there have been only two controlled trials that investigated the effect of THC on TS [194], both of which reported a significant improvement of tics and OCB after THC administration [195, 196].

See also  Proper dosage for cbd oil

Considering the relevance of these data, the need for alternative treatments for PD motor and nonmotor symptoms, medical marijuana, or related compounds may provide a new approach to the treatment of Parkinson’s disease.

4. Beneficial Effects of Cannabinoids in the Amelioration of Nonmotor Symptoms and Progression of Parkinson’s Disease

4.1. Neuroprotective Actions of Cannabinoids

Cannabinoids have been shown to have neuroprotective effect due to their antioxidative, anti-inflammatory actions and their ability to suppress exitotoxicity. Plant-derived cannabinoids such as THC and CBD can provide neuroprotection against the in vivo and in vitro toxicity of 6-hydroxydopamine and this was thought to be due to their antioxidative property or modulation of glial cell function or a combination of both [182]. Studies found that CBD was able to recover 6-hydroxydopamine-induced dopamine depletion and also induced upregulation of Cu, Zn-superoxide dismutase, which is a key enzyme in endogenous defense against oxidative stress [70, 191, 227]. The reported data suggest that CBD also diminishes the increase in nicotinamide adenine dinucleotide phosphate (NADPH) oxidase expression and decreases the markers of oxidative stress, inflammation, and cell death in the kidneys [228]. Another study has also emphasized a role for superoxide anion produced by microglial NADPH oxidase in augmenting the demise of dopaminergic neurons in the PD brain [229]. The mechanism by which CBD acts to reduce NADPH oxidase expression and inhibit oxidative injury within the PD brain has yet to be confirmed but it seems to act through mechanisms independent of CB1 or CB2 receptors [76]. However, data obtained from recent studies have hinted towards a direct relationship between the CB1 receptor and mitochondrial functions in the brain [230]. The phenolic ring moieties in cannabinoids display antioxidant activity guarding against glutamate-induced neurotoxicity in a cellular model [231]. CBD produced reduction of hydroperoxide-induced oxidative damage and was more protective against glutamate neurotoxicity compared to ascorbate and a-tocopherol, indicating that CBD is a potent antioxidant [232]. Taken together, these discoveries support the hypothesis that treatment with cannabinoids having antioxidant effects may modulate mitochondrial reactive oxygen species production [233] in the PD brain.

Inflammation has been shown to be a crucial pathological factor responsible for the demise of dopaminergic neurons in PD [234–236]. Glial cells appear to play a key role in neuroinflammation, since higher levels of activated microglia are reported in the substantia nigra of patients with PD compared to brains of control subjects [237, 238]. Cannabinoids demonstrate anti-inflammatory activities by suppressing toxic cytokine release and microglia activation [181–183]. Increased CB2 receptor expression in nigral cells and stimulation of these receptors protect dopaminergic neurons from microglia-induced inflammation and regulate neuronal survival [70]. The cannabinoids are known to be able to activate the CB2 receptor, which mediate the anti-inflammatory effects of the compounds and preserve cells from excessive apoptosis. Recent evidence substantiates that some cannabinoids may attenuate the neuroinflammation associated with PD [191, 239–241]. Several studies showed that CBD has anti-inflammatory properties [242–246] and can produce beneficial effect in acute inflammation and chronic neuropathic states [5, 247, 248]. THC demonstrates anti-inflammatory effect via activation of the CB1 receptor [249–251]. In addition, cannabinoids provide anti-inflammation effect by reducing the vasoconstriction and restoring blood supply to the injured area [252]. All these data support that cannabinoids are potentially effective compounds for the treatment of neuroinflammatory conditions, including neurodegenerative diseases like PD.

Marijuana may prevent brain damage by protecting against neuronal injury. There are a few mechanisms by which cannabinoids provide neuroprotection. One of the mechanisms involves an induction/upregulation of cannabinoid CB2 receptors, mainly in reactive microglia, and regulates the influence of these glial cells on homeostasis of surrounding neurons [253]. In combination with the increased antitoxic effects observed in cell cultures containing glia, this suggests that immunomodulation produced by CB2 receptor activation may play a primary role in the neuroprotective properties of cannabinoids [182]. Another mechanism of neuroprotection is activation of CB1 receptors. Loss of dopaminergic neurons and greater degree of motor impairment in CB1 knockout mice have been reported [85]. Cannabinoids activating the CB1 receptor are antiexcitotoxic due to suppression of glutamatergic activity with a subsequent decrease in calcium ion influx and eventual nitric oxide production [254–256]. Sativex-like combination of phytocannabinoids has been demonstrated to produce neuroprotective effect via interaction with both CB1 and CB2 receptors [134, 257]. In addition, THC reduced the loss of tyrosine hydroxylase-positive neurons in the substantia nigra [70] and exhibited neuroprotective effect by activation of the PPARγ receptors [258]. Overall, these data suggest that cannabinoids are neuroprotective in acute and chronic neurodegeneration and can delay or even stop progressive degeneration of brain dopaminergic system, a process that cannot be prevented currently.

4.2. Analgesic Effect of Cannabinoids

Pain is a relevant and often underestimated nonmotor symptom of PD [259, 260]. Pain affects more that 50% of people with this disorder and can cause extreme physical, psychological, and social disorders and worsen Parkinsonian disability [261, 262]. Different treatment options are used to treat PD pain [262–265]. However, these medications have significant side effects and do not provide universal efficacy [264, 265]. Cannabis is well known as a pain-relieving plant. The cannabinoid receptors in the central and peripheral nervous systems have been shown to modulate pain perception [266, 267].

Several clinical studies have been performed to investigate the effect of marijuana or cannabinoids on pain. Smoked cannabis significantly reduced neuropathic pain intensity as well as significantly improved mood disturbance, physical disability, and quality of life in HIV-patients [268]. Cannabis was effective at ameliorating neuropathic pain in patients with central and peripheral neuropathic pain [269]. Inhaled cannabis significantly reduced pain intensity (34%) compared to placebo in a clinical trial of painful distal symmetric polyneuropathy (DSPN) [270]. Whole plant extracts of Cannabis sativa produced statistically significant improvements on the mean pain severity score [271]. Cannabis-based medicine significantly decreased chronic pain intensity as well as sleep disturbance in multiple sclerosis patients [272, 273]. Oromucosal nabiximols (1 : 1 combination of the THC and CBD) produced a reduction in pain intensity scores in patients with neuropathic pain [274].

These findings are consistent with other discoveries supporting the efficacy of cannabis in relieving pain. The analgesic effect of cannabinoids has been reviewed [75, 211, 275–281]. The review of the literature suggests that marijuana and/or cannabinoids may be efficacious for pain relieving in various disease states including PD.

4.3. Antidepressant Effect of Cannabinoids

Depression is one of the common nonmotor symptoms of PD and the estimated rate varies widely, with an average prevalence of up to 50%. [282–284]. Despite its association with poor health outcomes and quality of life, depression in PD patients is underdiagnosed and undertreated [285–287]. Studies have indicated that the endocannabinoid system is involved in the regulation of mood and emotional behavior, and the loss or blockade of the endocannabinoid signaling system results in depressive symptoms [288]. For example, the CB1 receptor antagonist rimonabant has been shown to induce symptoms of anxiety and depression [289–291]. In addition, polymorphism of the gene that encodes the CB1 receptor has been associated with depression in PD [292]. In animal models, low level of THC produced antidepressant activity and increased serotogenic activity via activation of the CB1 receptor [293]. Animal studies have also shown that inhibition of hydrolysis of the endocannabinoid anandamide exerts antidepressive effect [294] and resulted in an increased serotonergic and noradrenergic neuronal activity in the midbrain. Currently available antidepressant drugs act via increasing serotonin and/or noradrenaline levels. These, and many other studies, indicate that the cannabinoid system is a potential target for the development of novel antidepressant drugs. Epidemiological studies have demonstrated that people who used cannabis daily or weekly exhibit less depressed mood and more positive effect than nonusers of cannabis [295]. Other studies have shown an association between heavy cannabis use and depressive symptoms. However, it is not clear whether the increased depressive symptoms are due to cannabis use or other factors that increased the risk of both depression and heavy use of cannabis [296]. Therefore, moderate use of cannabis in PD patients may help alleviate depressive symptoms and improve quality of life.

4.4. Effect of Cannabinoids on Sleep Disorders

Sleep disorders are common in PD patients and negatively affect the quality of life. The reported prevalence ranges from 25% to 98% and this wide variation could be due to differences in study design and diagnostic tools used [297]. The causes of the sleep disturbances in PD are multifactorial and include neurodegeneration and the medications used to treat motor symptoms of PD [298]. Various sleep disorders including rapid eye movement sleep behavior disorder, insomnia, sleep fragmentation, excessive daytime sleepiness, restless legs syndrome, and obstructive sleep apnea have been described in PD patients [299, 300]. Cannabidiol, the major nonpsychotic component of marijuana, has been reported to improve rapid eye movement sleep behavior disorder in PD patients [68, 69]. Marijuana has also been shown to improve nonmotor symptoms of PD including sleep [65]. In clinical trials involving 2000 patients with various pain conditions, nabiximols has been demonstrated to improve subjective sleep parameters [301]. Thus, marijuana could be used to enhance the quality of life of PD patients by alleviating sleep disorders and pain.

5. Summary

Cannabis and related compounds have recently been studied as promising therapeutic agents in treatment of neurodegenerative and movement disorders including Parkinson’s disease. In this review we have examined the potential benefits of medical marijuana and cannabinoids in the treatment of both motor and nonmotor symptoms as well as in slowing the progression of the disease. We have looked into any scientific evidence that indicates the potential use of marijuana and/or related compounds for the treatment of PD. Current treatments of PD provide only relief of motor symptoms and are associated with adverse effects such as dyskinesia. In addition, these therapies do not slow the progression of the disease. Therefore, there is an urgent need for safer drugs that can treat both motor and nonmotor symptoms of PD as well as drugs that slow the progression of the disease.

In spite of the placement of marijuana in schedule 1 category under the US Federal Controlled Substance Act, 24 states and Washington DC have enacted laws allowing the use of marijuana to treat a range of medical conditions. Parkinson’s disease has been listed as one of the disease conditions for which medical marijuana is allowed in a number of states. Research studies have provided evidence for the potential effectiveness of medical marijuana and its components in the treatment of PD as cannabinoids act on the same neurological pathway that is disrupted in Parkinson’s disease. Involvement of the endocannabinoid system in the regulation of motor behavior, the localization of the cannabinoid receptors in areas that control movement, and the effect of cannabinoids on motor activity indicate that cannabinoids can be potentially used in the treatment of movement disorders. Cannabinoid agonists and antagonists have been shown to modulate the endocannabinoid system and modify motor activity. Cannabinoid receptor antagonists appear to produce antiparkinsonian effects while cannabinoid receptor agonists exert a powerful motor inhibition and may be useful in the treatment of motor complications. In addition, we have assessed the role of the cannabinoid system and marijuana constituents in neuroprotection as well as considered other beneficial effects of marijuana. Marijuana has been shown to improve nonmotor symptoms of PD such as depression, pain, sleep, and anxiety. Moreover, components of cannabis have been demonstrated to have neuroprotective effect due to their anti-inflammatory, antioxidative, and antiexcitotoxic properties. Due to combination of the above mentioned beneficial effects, cannabis may provide a viable alternative or addition to the current treatment of Parkinson’s disease. However, there are concerns regarding the use of medical marijuana including lack of standardization and regulation, imprecise dosing, possible adverse effects, and medication interactions. Further studies are needed to provide more data on efficacy, safety, pharmacokinetics, and interactions of cannabinoids.

Competing Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

References

1. Borgelt L. M., Franson K. L., Nussbaum A. M., Wang G. S. The pharmacologic and clinical effects of medical cannabis. Pharmacotherapy. 2013; 33 (2):195–209. doi: 10.1002/phar.1187. [PubMed] [CrossRef] [Google Scholar]

2. ElSohly M. A., Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sciences. 2005; 78 (5):539–548. doi: 10.1016/j.lfs.2005.09.011. [PubMed] [CrossRef] [Google Scholar]

3. Russo E. B. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology. 2011; 163 (7):1344–1364. doi: 10.1111/j.1476-5381.2011.01238.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

4. Rahn E. J., Hohmann A. G. Cannabinoids as Pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009; 6 (4):713–737. doi: 10.1016/j.nurt.2009.08.002. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

5. Zuardi A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Revista Brasileira de Psiquiatria. 2008; 30 (3):271–280. doi: 10.1590/s1516-44462008000300015. [PubMed] [CrossRef] [Google Scholar]

6. Leweke F. M., Piomelli D., Pahlisch F., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry. 2012; 2 (3, article e94) doi: 10.1038/tp.2012.15. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

8. ONDCP (Office of National Drug Control Policy) Marijuana Resource Center: State Laws Related to Marijuana, https://www.whitehouse.gov/ondcp/state-laws-related-to-marijuana.

9. Park Y. Georgia Regents University. Epidiolex and Drug Resistant Epilepsy in Children (CBD) In: ClinicalTrials.gov. Bethesda (MD): National Library of Medicine (US). NLM Identifier: NCT02397863, https://clinicaltrials.gov/ct2/show/ > NCT02397863.

10. Notcutt W., Langford R., Davies P., Ratcliffe S., Potts R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex (nabiximols) Multiple Sclerosis Journal. 2012; 18 (2):219–228. doi: 10.1177/1352458511419700. [PubMed] [CrossRef] [Google Scholar]

11. Novotna A., Mares J., Ratcliffe S., et al. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols ∗ (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. European Journal of Neurology. 2011; 18 (9):1122–1131. doi: 10.1111/j.1468-1331.2010.03328.x. [PubMed] [CrossRef] [Google Scholar]

12. Grotenhermen F., Müller-Vahl K. The therapeutic potential of cannabis and cannabinoids. Deutsches Arzteblatt International. 2012; 109 (29-30):495–501. doi: 10.3238/arztebl.2012.0495. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

13. Scuderi C., De Filippis D., Iuvone T., Blasio A., Steardo A., Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Research. 2009; 23 (5):597–602. doi: 10.1002/ptr.2625. [PubMed] [CrossRef] [Google Scholar]

14. Iuvone T., Esposito G., De Filippis D., Scuderi C., Steardo L. Cannabidiol: a promising drug for neurodegenerative disorders? CNS Neuroscience and Therapeutics. 2009; 15 (1):65–75. doi: 10.1111/j.1755-5949.2008.00065.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

15. Hill A. J., Williams C. M., Whalley B. J., Stephens G. J. Phytocannabinoids as novel therapeutic agents in CNS disorders. Pharmacology and Therapeutics. 2012; 133 (1):79–97. doi: 10.1016/j.pharmthera.2011.09.002. [PubMed] [CrossRef] [Google Scholar]

16. Fusar-Poli P., Crippa J. A., Bhattacharyya S., et al. Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry Journal. 2009; 66 (1):95–105. doi: 10.1001/archgenpsychiatry.2008.519. [PubMed] [CrossRef] [Google Scholar]

17. Malone D. T., Hill M. N., Rubino T. Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models. British Journal of Pharmacology. 2010; 160 (3):511–522. doi: 10.1111/j.1476-5381.2010.00721.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

18. Gerra G., Zaimovic A., Gerra M. L., et al. Pharmacology and toxicology of cannabis derivatives and endocannabinoid agonists. Recent Patents on CNS Drug Discovery. 2010; 5 (1):46–52. doi: 10.2174/157488910789753521. [PubMed] [CrossRef] [Google Scholar]

19. Moore T. H., Zammit S., Lingford-Hughes A., et al. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. The Lancet. 2007; 370 (9584):319–328. doi: 10.1016/s0140-6736(07)61162-3. [PubMed] [CrossRef] [Google Scholar]

20. Bossong M. G., Niesink R. J. M. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Progress in Neurobiology. 2010; 92 (3):370–385. doi: 10.1016/j.pneurobio.2010.06.010. [PubMed] [CrossRef] [Google Scholar]

21. Schneider M. Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addiction Biology. 2008; 13 (2):253–263. doi: 10.1111/j.1369-1600.2008.00110.x. [PubMed] [CrossRef] [Google Scholar]

22. Grotenhermen F. The toxicology of cannabis and cannabis prohibition. Chemistry & Biodiversity. 2007; 4 (8):1744–1769. doi: 10.1002/cbdv.200790151. [PubMed] [CrossRef] [Google Scholar]

23. de Fonseca F. R., del Arco I., Bermudez-Silva F. J., Bilbao A., Cippitelli A., Navarro M. The endocannabinoid system: physiology and pharmacology. Alcohol and Alcoholism. 2005; 40 (1):2–14. [PubMed] [Google Scholar]

24. Pacher P., Bátkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacological Reviews. 2006; 58 (3):389–462. doi: 10.1124/pr.58.3.2. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

25. Morera-Herreras T., Miguelez C., Aristieta A., Ruiz-Ortega J. A., Ugedo L. Endocannabinoid modulation of dopaminergic motor circuits. Frontiers in Pharmacology. 2012; 3, article 110 doi: 10.3389/fphar.2012.00110. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

26. El Manira A., Kyriakatos A. The role of endocannabinoid signaling in motor control. Physiology. 2010; 25 (4):230–238. doi: 10.1152/physiol.00007.2010. [PubMed] [CrossRef] [Google Scholar]

27. Fernández-Ruiz J., González S. Cannabinoid control of motor function at the Basal Ganglia. Handbook of Experimental Pharmacology. 2005; 168 :479–507. doi: 10.1007/3-540-26573-2-16. [PubMed] [CrossRef] [Google Scholar]

28. Xu J., Kochanek K. D., Murphy S. L. National vital statistics reports deaths: final data for 2007. Statistics. 2010; 58 (3):p. 135. [Google Scholar]

29. Pringsheim T., Jette N., Frolkis A., Steeves T. D. L. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Movement Disorders. 2014; 29 (13):1583–1590. doi: 10.1002/mds.25945. [PubMed] [CrossRef] [Google Scholar]

30. Dorsey E. R., Constantinescu R., Thompson J. P., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007; 68 (5):384–386. doi: 10.1212/01.wnl.0000247740.47667.03. [PubMed] [CrossRef] [Google Scholar]

31. Tan L. C. S. Epidemiology of parkinson’s disease. Neurology Asia. 2013; 18 (3):231–238. [Google Scholar]

32. Galvan A., Wichmann T. Pathophysiology of Parkinsonism. Clinical Neurophysiology. 2008; 119 (7):1459–1474. doi: 10.1016/j.clinph.2008.03.017. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

33. Kwan L. C., Whitehill T. L. Perception of speech by individuals with Parkinson’s disease: a review. Parkinson’s Disease. 2011; 2011 :11. doi: 10.4061/2011/389767. 389767 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

34. Thomas B., Beal M. F. Parkinson’s disease. Human Molecular Genetics. 2007; 16 (2):R183–R194. doi: 10.1093/hmg/ddm159. [PubMed] [CrossRef] [Google Scholar]

35. Alexander G. E. Biology of Parkinson’s disease: pathogenesis and pathophysiology of a multisystem neurodegenerative disorder. Dialogues in Clinical Neuroscience. 2004; 6 (3):259–280. [PMC free article] [PubMed] [Google Scholar]

36. Dauer W., Przedborski S. Parkinson’s disease: mechanisms and models. Neuron. 2003; 39 (6):889–909. doi: 10.1016/s0896-6273(03)00568-3. [PubMed] [CrossRef] [Google Scholar]

37. Rodriguez-Oroz M. C., Jahanshahi M., Krack P., et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. The Lancet Neurology. 2009; 8 (12):1128–1139. doi: 10.1016/s1474-4422(09)70293-5. [PubMed] [CrossRef] [Google Scholar]

38. Patel T., Chang F. Parkinson’s disease guidelines for pharmacists. Canadian Pharmacists Journal. 2014; 147 (3):161–170. doi: 10.1177/1715163514529740. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

39. Chaudhuri K. R., Healy D. G., Schapira A. H. V. Non-motor symptoms of Parkinson’s disease: diagnosis and management. The Lancet Neurology. 2006; 5 (3):235–245. doi: 10.1016/s1474-4422(06)70373-8. [PubMed] [CrossRef] [Google Scholar]

40. Müller B., Assmus J., Herlofson K., Larsen J. P., Tysnes O.-B. Importance of motor vs. non-motor symptoms for health-related quality of life in early Parkinson’s disease. Parkinsonism and Related Disorders. 2013; 19 (11):1027–1032. doi: 10.1016/j.parkreldis.2013.07.010. [PubMed] [CrossRef] [Google Scholar]

41. Latoo J., Mistry M., Dunne F. J. Often overlooked neuropsychiatric syndromes in Parkinson’s disease. British Journal of Medical Practitioners. 2013; 6 (1):23–30. [Google Scholar]

42. Stocchi F., Abbruzzese G., Ceravolo R., et al. Prevalence of fatigue in Parkinson disease and its clinical correlates. Neurology. 2014; 83 (3):215–220. doi: 10.1212/WNL.0000000000000587. [PubMed] [CrossRef] [Google Scholar]

43. Velseboer D. C., de Haan R. J., Wieling W., Goldstein D. S., de Bie R. M. A. Prevalence of orthostatic hypotension in Parkinson’s disease: a systematic review and meta-analysis. Parkinsonism and Related Disorders. 2011; 17 (10):724–729. doi: 10.1016/j.parkreldis.2011.04.016. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

44. Connolly B., Fox S. H. Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson’s disease. Neurotherapeutics. 2014; 11 (1):78–91. doi: 10.1007/s13311-013-0238-x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

45. Huot P., Fox S. H., Brotchie J. M. Monoamine reuptake inhibitors in Parkinson’s disease. Parkinson’s Disease. 2015; 2015 :71. doi: 10.1155/2015/609428. 609428 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

46. Gasparini F., Di Paolo T., Gomez-Mancilla B. Metabotropic glutamate receptors for Parkinson’s disease therapy. Parkinson’s Disease. 2013; 2013 :11. doi: 10.1155/2013/196028. 196028 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

47. Goetz C. G., Pal G. Initial management of Parkinson’s disease. British Medical Journal. 2014; 349 doi: 10.1136/bmj.g6258. 6258 [PubMed] [CrossRef] [Google Scholar]

48. Lees A. Alternatives to levodopa in the initial treatment of early Parkinson’s disease. Drugs and Aging. 2005; 22 (9):731–740. doi: 10.2165/00002512-200522090-00002. [PubMed] [CrossRef] [Google Scholar]

49. Katzenschlager R., Sampaio C., Costa J., Lees A. Anticholinergics for symptomatic management of Parkinson’s disease. Cochrane Database of Systematic Reviews. 2003;(2) CD003735 [PMC free article] [PubMed] [Google Scholar]

50. Maranis S., Tsouli S., Konitsiotis S. Treatment of motor symptoms in advanced Parkinson’s disease: a practical approach. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011; 35 (8):1795–1807. doi: 10.1016/j.pnpbp.2011.05.014. [PubMed] [CrossRef] [Google Scholar]

51. Heumann R., Moratalla R., Herrero M. T., et al. Dyskinesia in Parkinson’s disease: mechanisms and current non-pharmacological interventions. Journal of Neurochemistry. 2014; 130 (4):472–489. doi: 10.1111/jnc.12751. [PubMed] [CrossRef] [Google Scholar]

52. Politis M., Wu K., Loane C., et al. Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson’s disease patients. The Journal of Clinical Investigation. 2014; 124 (3):1340–1349. doi: 10.1172/jci71640. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

53. Porras G., De Deurwaerdere P., Li Q., et al. L-dopa-induced dyskinesia: beyond an excessive dopamine tone in the striatum. Scientific Reports. 2014; 4, article 3730 doi: 10.1038/srep03730. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

54. Chen J. J., Swope D. M., Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson’s Disease. Clinical Therapeutics. 2007; 29 (9):1825–1849. doi: 10.1016/j.clinthera.2007.09.021. [PubMed] [CrossRef] [Google Scholar]

55. Lecht S., Haroutiunian S., Hoffman A., Lazarovici P. Rasagiline—a novel MAO B inhibitor in Parkinson’s disease therapy. Therapeutics and Clinical Risk Management. 2007; 3 (3):467–474. [PMC free article] [PubMed] [Google Scholar]

56. Pahwa R., Factor S. A., Lyons K. E., et al. Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006; 66 (7):983–995. doi: 10.1212/01.wnl.0000215250.82576.87. [PubMed] [CrossRef] [Google Scholar]

57. Stocchi F., Rabey J. M. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson’s disease. European Journal of Neurology. 2011; 18 (12):1373–1378. doi: 10.1111/j.1468-1331.2011.03512.x. [PubMed] [CrossRef] [Google Scholar]

58. Rascol O., Brooks D. J., Melamed E., et al. Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. The Lancet Neurology. 2005; 365 :947–954. [PubMed] [Google Scholar]

59. Tolosa E., Stern M. B. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson’s disease. European Journal of Neurology. 2012; 19 (2):258–264. doi: 10.1111/j.1468-1331.2011.03484.x. [PubMed] [CrossRef] [Google Scholar]

60. Rascol O., Brooks D. J., Korczyn A. D., De Deyn P. P., Clarke C. E., Lang A. E. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. The New England Journal of Medicine. 2000; 342 (20):1484–1491. doi: 10.1056/nejm200005183422004. [PubMed] [CrossRef] [Google Scholar]

61. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group. The Journal of the American Medical Association. 2000; 284 (15):1931–1938. doi: 10.1001/jama.284.15.1931. [PubMed] [CrossRef] [Google Scholar]

62. Perez-Lloret S., Rey M. V., Ratti P. L., Rascol O. Rotigotine transdermal patch for the treatment of Parkinson’s disease. Fundamental and Clinical Pharmacology. 2013; 27 (1):81–95. doi: 10.1111/j.1472-8206.2012.01028.x. [PubMed] [CrossRef] [Google Scholar]

63. Elshoff J.-P., Cawello W., Andreas J.-O., Mathy F.-X., Braun M. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson’s disease and restless legs syndrome. Drugs. 2015; 75 (5):487–501. doi: 10.1007/s40265-015-0377-y. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

64. Deleu D., Hanssens Y., Northway M. G. Subcutaneous apomorphine: an evidence-based review of its use in Parkinson’s disease. Drugs and Aging. 2004; 21 (11):687–709. doi: 10.2165/00002512-200421110-00001. [PubMed] [CrossRef] [Google Scholar]

65. Lotan I., Treves T. A., Roditi Y., Djaldetti R. Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease. Clinical Neuropharmacology. 2014; 37 (2):41–44. [PubMed] [Google Scholar]

66. Finseth T. A., Hedeman J. L., Brown R. P., Johnson K. I., Binder M. S., Kluger B. M. Self-reported efficacy of cannabis and other complementary medicine modalities by Parkinson’s disease patients in Colorado. Evidence-Based Complementary and Alternative Medicine. 2015; 2015 :6. doi: 10.1155/2015/874849. 874849 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

67. Zuardi A. W., Crippa J. A. S., Hallak J. E. C., et al. Cannabidiol for the treatment of psychosis in Parkinson’s disease. Journal of Psychopharmacology. 2009; 23 (8):979–983. doi: 10.1177/0269881108096519. [PubMed] [CrossRef] [Google Scholar]

68. Chagas M. H. N., Zuardi A. W., Tumas V., et al. Effects of cannabidiol in the treatment of patients with Parkinson’s disease: an exploratory double-blind trial. Journal of Psychopharmacology. 2014; 28 (11):1088–1092. doi: 10.1177/0269881114550355. [PubMed] [CrossRef] [Google Scholar]

69. Chagas M. H. N., Eckeli A. L., Zuardi A. W., et al. Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Journal of Clinical Pharmacy and Therapeutics. 2014; 39 (5):564–566. doi: 10.1111/jcpt.12179. [PubMed] [CrossRef] [Google Scholar]

70. García C., Palomo-Garo C., García-Arencibia M., Ramos J. A., Pertwee R. G., Fernández-Ruiz J. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9 -THCV in animal models of Parkinson’s disease. British Journal of Pharmacology. 2011; 163 (7):1495–1506. doi: 10.1111/j.1476-5381.2011.01278.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

71. Shen M., Thayer S. A. Δ 9 -Tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture. Molecular Pharmacology. 1999; 55 (1):8–13. [PubMed] [Google Scholar]

72. Murase R., Kawamura R., Singer E., et al. Targeting multiple cannabinoid anti-tumour pathways with a resorcinol derivative leads to inhibition of advanced stages of breast cancer. British Journal of Pharmacology. 2014; 171 (19):4464–4477. doi: 10.1111/bph.12803. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

73. Devinsky O., Cilio M. R., Cross H., et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014; 55 (6):791–802. doi: 10.1111/epi.12631. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

74. Babayeva M., Fuzailov M., Rozenfeld P., Basu P. Marijuana compounds: a non-conventional therapeutic approach to epilepsy in children. Journal of Addiction Neuropharmacology. 2014; 1 :2–36. [Google Scholar]

75. Croxford J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs. 2003; 17 (3):179–202. doi: 10.2165/00023210-200317030-00004. [PubMed] [CrossRef] [Google Scholar]

76. Fernández-Ruiz J., Sagredo O., Pazos M. R., et al. Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? British Journal of Clinical Pharmacology. 2013; 75 (2):323–333. doi: 10.1111/j.1365-2125.2012.04341.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

77. Hashimotodani Y., Ohno-Shosaku T., Watanabe M., Kano M. Roles of phospholipase Cβ and NMDA receptor in activity-dependent endocannabinoid release. The Journal of Physiology. 2007; 584 (2):373–380. doi: 10.1113/jphysiol.2007.137497. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

78. Hegyi Z., Holló K., Kis G., Mackie K., Antal M. Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. Glia. 2012; 60 (9):1316–1329. doi: 10.1002/glia.22351. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

79. Fine P. G., Rosenfeld M. J. The endocannabinoid system, cannabinoids, and pain. Rambam Maimonides Medical Journal. 2013; 4 (4) doi: 10.5041/rmmj.10129. e0022 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

80. Marco E. M., Romero-Zerbo S. Y., Viveros M.-P., Bermudez-Silva F. J. The role of the endocannabinoid system in eating disorders: pharmacological implications. Behavioural Pharmacology. 2012; 23 (5-6):526–536. doi: 10.1097/fbp.0b013e328356c3c9. [PubMed] [CrossRef] [Google Scholar]

81. Hiley C. R. Endocannabinoids and the heart. Journal of Cardiovascular Pharmacology. 2009; 53 (4):267–276. doi: 10.1097/FJC.0b013e318192671d. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

82. Pertwee R. G. The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: Δ 9-tetrahydrocannabinol, cannabidiol and Δ 9-tetrahydrocannabivarin. British Journal of Pharmacology. 2008; 153 (2):199–215. doi: 10.1038/sj.bjp.0707442. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

83. Xu J.-Y., Chen C. Endocannabinoids in synaptic plasticity and neuroprotection. Neuroscientist. 2015; 21 (2):152–168. doi: 10.1177/1073858414524632. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

84. Hegde V. L., Nagarkatti M., Nagarkatti P. S. Cannabinoid receptor activation leads to massive mobilization of myeloid-derived suppressor cells with potent immunosuppressive properties. European Journal of Immunology. 2010; 40 (12):3358–3371. doi: 10.1002/eji.201040667. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

85. Pérez-Rial S., García-Gutiérrez M. S., Molina J. A., et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. Neurobiology of Aging. 2011; 32 (4):631–645. doi: 10.1016/j.neurobiolaging.2009.03.017. [PubMed] [CrossRef] [Google Scholar]

86. Piomelli D. The molecular logic of endocannabinoid signalling. Nature Reviews Neuroscience. 2003; 4 (11):873–884. doi: 10.1038/nrn1247. [PubMed] [CrossRef] [Google Scholar]

87. Matsuda L. A., Lolait S. J., Brownstein M. J., Young A. C., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 1990; 346 (6284):561–564. doi: 10.1038/346561a0. [PubMed] [CrossRef] [Google Scholar]

88. Herkenham M., Lynn A. B., Little M. D., et al. Cannabinoid receptor localization in brain. Proceedings of the National Academy of Sciences of the United States of America. 1990; 87 (5):1932–1936. doi: 10.1073/pnas.87.5.1932. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

89. Ivanov I., Borchert P., Hinz B. A simple method for simultaneous determination of N-arachidonoylethanolamine, N-oleoylethanolamine, N-palmitoylethanolamine and 2-arachidonoylglycerol in human cells. Analytical and Bioanalytical Chemistry. 2015; 407 (6):1781–1787. doi: 10.1007/s00216-014-8384-5. [PubMed] [CrossRef] [Google Scholar]

90. Pertwee R. G., Howlett A. C., Abood M. E., et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB1 and CB2. Pharmacological Reviews. 2010; 62 (4):588–631. doi: 10.1124/pr.110.003004. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

91. Snider N. T., Walker V. J., Hollenberg P. F. Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications. Pharmacological Reviews. 2010; 62 (1):136–154. doi: 10.1124/pr.109.001081. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

92. Buczynski M. W., Parsons L. H. Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls. British Journal of Pharmacology. 2010; 160 (3):423–442. doi: 10.1111/j.1476-5381.2010.00787.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

93. Felder C. C., Nielsen A., Briley E. M., et al. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Letters. 1996; 393 (2-3):231–235. doi: 10.1016/0014-5793(96)00891-5. [PubMed] [CrossRef] [Google Scholar]

94. Sugiura T., Kondo S., Kishimoto S., et al. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. Journal of Biological Chemistry. 2000; 275 (1):605–612. doi: 10.1074/jbc.275.1.605. [PubMed] [CrossRef] [Google Scholar]

95. Bisogno T., Berrendero F., Ambrosino G., et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochemical and Biophysical Research Communications. 1999; 256 (2):377–380. [PubMed] [Google Scholar]

96. Mechoulam R., Ben-Shabat S., Hanus L., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochemical Pharmacology. 1995; 50 (1):83–90. doi: 10.1016/0006-2952(95)00109-D. [PubMed] [CrossRef] [Google Scholar]

97. Gonsiorek W., Lunn C., Fan X., Narula S., Lundell D., Hipkin R. W. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. Molecular Pharmacology. 2000; 57 (5):1045–1050. [PubMed] [Google Scholar]

98. Di Marzo V., Berrendero F., Bisogno T., et al. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of Δ9- tetrahydrocannabinol-tolerant rats. Journal of Neurochemistry. 2000; 74 (4):1627–1635. doi: 10.1046/j.1471-4159.2000.0741627.x. [PubMed] [CrossRef] [Google Scholar]

99. Di Marzo V., Hill M. P., Bisogno T., Crossman A. R., Brotchie J. M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson’s disease. FASEB Journal. 2000; 14 (10):1432–1438. doi: 10.1096/fj.14.10.1432. [PubMed] [CrossRef] [Google Scholar]

100. Palermo G., Bauer I., Campomanes P., et al. Keys to lipid selection in fatty acid amide hydrolase catalysis: structural flexibility, gating residues and multiple binding pockets. PLoS Computational Biology. 2015; 11 (6, article e1004231) doi: 10.1371/journal.pcbi.1004231. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

101. Giuffrida A., Parsons L. H., Kerr T. M., Rodríguez De Fonseca F., Navarro M., Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nature Neuroscience. 1999; 2 (4):358–363. doi: 10.1038/7268. [PubMed] [CrossRef] [Google Scholar]

102. De Petrocellis L., Cascio M. G., Di Marzo V. The endocannabinoid system: a general view and latest additions. British Journal of Pharmacology. 2004; 141 (5):765–774. doi: 10.1038/sj.bjp.0705666. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

103. Basavarajappa B. S. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Current Neuropharmacology. 2007; 5 (2):81–97. doi: 10.2174/157015907780866910. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

104. Karniol I. G., Carlini E. A. Pharmacological interaction between cannabidiol and δ9-tetrahydrocannabinol. Psychopharmacologia. 1973; 33 (1):53–70. doi: 10.1007/BF00428793. [PubMed] [CrossRef] [Google Scholar]

105. Mechoulam R., Shvo Y. Hashish—I: the structure of cannabidiol. Tetrahedron. 1963; 19 :2073–2078. [PubMed] [Google Scholar]

106. Di Marzo V., Fontana A. Anandamide, an endogenous cannabinomimetic eicosanoid: ‘killing two birds with one stone’ Prostaglandins, Leukotrienes and Essential Fatty Acids. 1995; 53 (1):1–11. doi: 10.1016/0952-3278(95)90077-2. [PubMed] [CrossRef] [Google Scholar]

107. Groenewegen H. J. The basal ganglia and motor control. Neural Plasticity. 2003; 10 (1-2):107–120. doi: 10.1155/np.2003.107. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

108. Calabresi P., Picconi B., Tozzi A., Ghiglieri V., Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nature Neuroscience. 2014; 17 (8):1022–1030. doi: 10.1038/nn.3743. [PubMed] [CrossRef] [Google Scholar]

109. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. British Journal of Pharmacology. 2009; 156 (7):1029–1040. doi: 10.1111/j.1476-5381.2008.00088.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

110. Heifets B. D., Castillo P. E. Endocannabinoid signaling and long-term synaptic plasticity. Annual Review of Physiology. 2009; 71 :283–306. doi: 10.1146/annurev.physiol.010908.163149. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

111. Bezard E., Brotchie J. M., Gross C. E. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Reviews Neuroscience. 2001; 2 (8):577–588. doi: 10.1038/35086062. [PubMed] [CrossRef] [Google Scholar]

112. More S. V., Choi D.-K. Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection. Molecular Neurodegeneration. 2015; 10 (1, article 17) doi: 10.1186/s13024-015-0012-0. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

113. García-Arencibia M., García C., Fernández-Ruiz J. Cannabinoids and Parkinson’s disease. CNS and Neurological Disorders—Drug Targets. 2009; 8 (6):432–439. doi: 10.2174/187152709789824642. [PubMed] [CrossRef] [Google Scholar]

114. Brotchie J. M. CB1 cannabinoid receptor signalling in Parkinson’s disease. Current Opinion in Pharmacology. 2003; 3 (1):54–61. doi: 10.1016/s1471-4892(02)00011-5. [PubMed] [CrossRef] [Google Scholar]

115. van der Stelt M., Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. European Journal of Pharmacology. 2003; 480 (1–3):133–150. doi: 10.1016/j.ejphar.2003.08.101. [PubMed] [CrossRef] [Google Scholar]

116. Benarroch E. Endocannabinoids in basal ganglia circuits: implications for Parkinson disease. Neurology. 2007; 69 (3):306–309. doi: 10.1212/01.wnl.0000267407.79757.75. [PubMed] [CrossRef] [Google Scholar]

117. Fusco F. R., Martorana A., Giampà C., et al. Immunolocalization of CB1 receptor in rat striatal neurons: A Confocal Microscopy Study. Synapse. 2004; 53 (3):159–167. doi: 10.1002/syn.20047. [PubMed] [CrossRef] [Google Scholar]

118. Di Filippo M., Picconi B., Tozzi A., Ghiglieri V., Rossi A., Calabresi P. The endocannabinoid system in Pakinson’s disease. Current Pharmaceutical Design. 2008; 14 (23):2337–2346. doi: 10.2174/138161208785740072. [PubMed] [CrossRef] [Google Scholar]

See also  How much cbd oil for 40 pound dog

119. Lastres-Becker I., Cebeira M., De Ceballos M. L., et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. European Journal of Neuroscience. 2001; 14 (11):1827–1832. doi: 10.1046/j.0953-816X.2001.01812.x. [PubMed] [CrossRef] [Google Scholar]

120. Lastres-Becker I., Fezza F., Cebeira M., et al. Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington’s disease. NeuroReport. 2001; 12 (10):2125–2129. doi: 10.1097/00001756-200107200-00017. [PubMed] [CrossRef] [Google Scholar]

121. Dawson T. M., Dawson V. L. Rare genetic mutations shed light on the pathogenesis of Parkinson disease. The Journal of Clinical Investigation. 2003; 111 (2):145–151. doi: 10.1172/jci200317575. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

122. González S., Mena M. A., Lastres-Becker I., et al. Cannabinoid CB1 receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice. Brain Research. 2005; 1046 (1-2):195–206. doi: 10.1016/j.brainres.2005.04.010. [PubMed] [CrossRef] [Google Scholar]

123. Wilson R. I., Nicoll R. A. Endocannabinoid signaling in the brain. Science. 2002; 296 (5568):678–682. doi: 10.1126/science.1063545. [PubMed] [CrossRef] [Google Scholar]

124. Meschler J. P., Conley T. J., Howlett A. C. Cannabinoid and dopamine interaction in rodent brain: effects on locomotor activity. Pharmacology Biochemistry and Behavior. 2000; 67 (3):567–573. doi: 10.1016/s0091-3057(00)00390-7. [PubMed] [CrossRef] [Google Scholar]

125. Meschler J. P., Howlett A. C., Madras B. K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology. 2001; 156 (1):79–85. doi: 10.1007/s002130100728. [PubMed] [CrossRef] [Google Scholar]

126. Batista L. A., Gobira P. H., Viana T. G., Aguiar D. C., Moreira F. A. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behavioural Pharmacology. 2014; 25 (5-6):425–433. doi: 10.1097/FBP.0000000000000073. [PubMed] [CrossRef] [Google Scholar]

127. Mezey É., Tóth Z. E., Cortright D. N., et al. Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1- like immunoreactivity, in the central nervous system of the rat and human. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97 (7):3655–3660. doi: 10.1073/pnas.060496197. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

128. Palazzo E., Rossi F., Maione S. Role of TRPV1 receptors in descending modulation of pain. Molecular and Cellular Endocrinology. 2008; 286 (1-2, supplement 1):S79–S83. doi: 10.1016/j.mce.2008.01.013. [PubMed] [CrossRef] [Google Scholar]

129. de Lago E., de Miguel R., Lastres-Becker I., Ramos J. A., Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Research. 2004; 1007 (1-2):152–159. doi: 10.1016/j.brainres.2004.02.016. [PubMed] [CrossRef] [Google Scholar]

130. dos Anjos-Garcia T., Ullah F., Falconi-Sobrinho L. L., Coimbra N. C. CB1 cannabinoid receptor-mediated anandamide signalling reduces the defensive behaviour evoked through GABAA receptor blockade in the dorsomedial division of the ventromedial hypothalamus. Neuropharmacology. 2016; 113 :156–166. doi: 10.1016/j.neuropharm.2016.04.003. [PubMed] [CrossRef] [Google Scholar]

131. Lizanecz E., Bagi Z., Pásztor E. T., et al. Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Molecular Pharmacology. 2006; 69 (3):1015–1023. doi: 10.1124/mol.105.015644. [PubMed] [CrossRef] [Google Scholar]

132. Kravitz A. V., Freeze B. S., Parker P. R. L., et al. Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry. Nature. 2010; 466 (7306):622–626. doi: 10.1038/nature09159. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

133. Kreitzer A. C., Malenka R. C. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 2007; 445 (7128):643–647. doi: 10.1038/nature05506. [PubMed] [CrossRef] [Google Scholar]

134. Sagredo O., Pazos M. R., Satta V., Ramos J. A., Pertwee R. G., Fernández-Ruiz J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. Journal of Neuroscience Research. 2011; 89 (9):1509–1518. doi: 10.1002/jnr.22682. [PubMed] [CrossRef] [Google Scholar]

135. Moss D. E., McMaster S. B., Rogers J. Tetrahydrocannabinol potentiates reserpine-induced hypokinesia. Pharmacology, Biochemistry and Behavior. 1981; 15 (5):779–783. doi: 10.1016/0091-3057(81)90022-8. [PubMed] [CrossRef] [Google Scholar]

136. Van Der Stelt M., Fox S. H., Hill M., et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson’s disease. FASEB Journal. 2005; 19 (9):1140–1142. doi: 10.1096/fj.04-3010fje. [PubMed] [CrossRef] [Google Scholar]

137. Bisogno T., Berrendero F., Ambrosino G., et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochemical and Biophysical Research Communications. 1999; 256 (2):377–380. doi: 10.1006/bbrc.1999.0254. [PubMed] [CrossRef] [Google Scholar]

138. Sañudo-Peña M. C., Tsou K., Walker J. M. Motor actions of cannabinoids in the basal ganglia output nuclei. Life Sciences. 1999; 65 (6-7):703–713. doi: 10.1016/s0024-3205(99)00293-3. [PubMed] [CrossRef] [Google Scholar]

139. Lastres-Becker I., Hansen H. H., Berrendero F., et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington’s disease. Synapse. 2002; 44 (1):23–35. doi: 10.1002/syn.10054. [PubMed] [CrossRef] [Google Scholar]

140. Glass M., Dragunow M., Faull R. L. The pattern of neurodegeneration in Huntington’s disease: a comparative study of cannabinoid, dopamine, adenosine and GABAA receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience. 2000; 97 (3):505–519. doi: 10.1016/s0306-4522(00)00008-7. [PubMed] [CrossRef] [Google Scholar]

141. Van Laere K., Casteels C., Lunskens S., et al. Regional changes in type 1 cannabinoid receptor availability in Parkinson’s disease in vivo. Neurobiology of Aging. 2012; 33 (3):620.e1–620.e8. doi: 10.1016/j.neurobiolaging.2011.02.009. [PubMed] [CrossRef] [Google Scholar]

142. Romero E. M., Fernández B., Sagredo O., et al. Antinociceptive, behavioural and neuroendocrine effects of CP 55,940 in young rats. Developmental Brain Research. 2002; 136 (2):85–92. doi: 10.1016/S0165-3806(02)00306-1. [PubMed] [CrossRef] [Google Scholar]

143. Long L. E., Chesworth R., Huang X.-F., McGregor I. S., Arnold J. C., Karl T. A behavioural comparison of acute and chronic 9- tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. International Journal of Neuropsychopharmacology. 2010; 13 (7):861–876. doi: 10.1017/S1461145709990605. [PubMed] [CrossRef] [Google Scholar]

144. Prescott W. R., Gold L. H., Martin B. R. Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by Δ 9 -THC in the rat. Psychopharmacology. 1992; 107 (1):117–124. doi: 10.1007/bf02244975. [PubMed] [CrossRef] [Google Scholar]

145. Crawley J. N., Corwin R. L., Robinson J. K., Felder C. C., Devane W. A., Axelrod J. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacology, Biochemistry and Behavior. 1993; 46 (4):967–972. doi: 10.1016/0091-3057(93)90230-Q. [PubMed] [CrossRef] [Google Scholar]

146. Romero J., de Miguel R., García-Palomero E., Fernández-Ruiz J. J., Ramos J. A. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function. Brain Research. 1995; 694 (1-2):223–232. doi: 10.1016/0006-8993(95)00835-E. [PubMed] [CrossRef] [Google Scholar]

147. Romero J., Garcia L., Cebeira M., Zadrozny D., Fernández-Ruiz J. J., Ramos J. A. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons. Life Sciences. 1995; 56 (23-24):2033–2040. doi: 10.1016/0024-3205(95)00186-A. [PubMed] [CrossRef] [Google Scholar]

148. Anderson L. A., Anderson J. J., Chase T. N., Walters J. R. The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway. Brain Research. 1995; 691 (1-2):106–114. doi: 10.1016/0006-8993(95)00645-7. [PubMed] [CrossRef] [Google Scholar]

149. Fernández-Ruiz J., Lastres-Becker I., Cabranes A., González S., Ramos J. A. Endocannabinoids and basal ganglia functionality. Prostaglandins Leukotrienes and Essential Fatty Acids. 2002; 66 (2-3):257–267. doi: 10.1054/plef.2001.0350. [PubMed] [CrossRef] [Google Scholar]

150. Herkenham M., Lynn A. B., Ross Johnson M., Melvin L. S., De Costa B. R., Rice K. C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. Journal of Neuroscience. 1991; 11 (2):563–583. [PMC free article] [PubMed] [Google Scholar]

151. Hohmann A. G., Herkenham M. Localization of cannabinoid CB1 receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse. 2000; 37 (1):71–80. doi: 10.1002/(sici)1098-2396(200007)37:13.0.co;2-k. [PubMed] [CrossRef] [Google Scholar]

152. Romero J., Lastres-Becker I., de Miguel R., Berrendero F., Ramos J. A., Fernández-Ruiz J. The endogenous cannabinoid system and the basal ganglia: biochemical, pharmacological, and therapeutic aspects. Pharmacology and Therapeutics. 2002; 95 (2):137–152. doi: 10.1016/s0163-7258(02)00253-x. [PubMed] [CrossRef] [Google Scholar]

153. Gubellini P., Picconi B., Bari M., et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. The Journal of Neuroscience. 2002; 22 (16):6900–6907. [PMC free article] [PubMed] [Google Scholar]

154. Gilgun-Sherki Y., Melamed E., Mechoulam R., Offen D. The CB1 cannabinoid receptor agonist, HU-210, reduces levodopa-induced rotations in 6-hydroxydopamine-lesioned rats. Pharmacology and Toxicology. 2003; 93 (2):66–70. doi: 10.1034/j.1600-0773.2003.930202.x. [PubMed] [CrossRef] [Google Scholar]

155. Malone D. T., Taylor D. A. Modulation by fluoxetine of striatal dopamine release following Δ 9 -tetrahydrocannabinol: a microdialysis study in conscious rats. British Journal of Pharmacology. 1999; 128 (1):21–26. doi: 10.1038/sj.bjp.0702753. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

156. Tanda G., Pontieri F. E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science. 1997; 276 (5321):2048–2050. doi: 10.1126/science.276.5321.2048. [PubMed] [CrossRef] [Google Scholar]

157. Pertwee R. G., Thomas A., Stevenson L. A., et al. The psychoactive plant cannabinoid, Δ 9- tetrahydrocannabinol, is antagonized by Δ 8- and Δ 9-tetrahydrocannabivarin in mice in vivo. British Journal of Pharmacology. 2007; 150 (5):586–594. doi: 10.1038/sj.bjp.0707124. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

158. Richter A., Löscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. European Journal of Pharmacology. 1994; 264 (3):371–377. doi: 10.1016/0014-2999(94)00490-0. [PubMed] [CrossRef] [Google Scholar]

159. Maneuf Y. P., Crossman A. R., Brotchie J. M. The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson’s disease. Experimental Neurology. 1997; 148 (1):265–270. doi: 10.1006/exnr.1997.6645. [PubMed] [CrossRef] [Google Scholar]

160. Segovia G., Mora F., Crossman A. R., Brotchie J. M. Effects of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson’s disease. Movement Disorders. 2003; 18 (2):138–149. doi: 10.1002/mds.10312. [PubMed] [CrossRef] [Google Scholar]

161. Morgese M. G., Cassano T., Cuomo V., Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson’s disease: role of CB1 and TRPV1 receptors. Experimental Neurology. 2007; 208 (1):110–119. doi: 10.1016/j.expneurol.2007.07.021. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

162. Morgese M. G., Cassano T., Gaetani S., et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochemistry International. 2009; 54 (1):56–64. doi: 10.1016/j.neuint.2008.10.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

163. Ferrer B., Asbrock N., Kathuria S., Piomelli D., Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. European Journal of Neuroscience. 2003; 18 (6):1607–1614. doi: 10.1046/j.1460-9568.2003.02896.x. [PubMed] [CrossRef] [Google Scholar]

164. González-Aparicio R., Moratalla R. Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson’s disease. Neurobiology of Disease. 2014; 62 :416–425. doi: 10.1016/j.nbd.2013.10.008. [PubMed] [CrossRef] [Google Scholar]

165. Fox S. H., Henry B., Hill M., Crossman A., Brotchie J. M. Stimulation of Cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson’s disease. Movement Disorders. 2002; 17 (6):1180–1187. doi: 10.1002/mds.10289. [PubMed] [CrossRef] [Google Scholar]

166. Fox S. H., Kellett M., Moore A. P., Crossman A. R., Brotchie J. M. Randomised, double-blind, placebo-controlled trial to assess the potential of cannabinoid receptor stimulation in the treatment of dystonia. Movement Disorders. 2002; 17 (1):145–149. doi: 10.1002/mds.1280. [PubMed] [CrossRef] [Google Scholar]

167. Solinas M., Justinova Z., Goldberg S. R., Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. Journal of Neurochemistry. 2006; 98 (2):408–419. doi: 10.1111/j.1471-4159.2006.03880.x. [PubMed] [CrossRef] [Google Scholar]

168. Zygmunt P. M., Petersson J., Andersson D. A., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999; 400 (6743):452–457. doi: 10.1038/22761. [PubMed] [CrossRef] [Google Scholar]

169. Smart D., Gunthorpe M. J., Jerman J. C., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) British Journal of Pharmacology. 2000; 129 (2):227–230. doi: 10.1038/sj.bjp.0703050. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

170. Di Marzo V., Lastres-Becker I., Bisogno T., et al. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. European Journal of Pharmacology. 2001; 420 (2-3):123–131. doi: 10.1016/S0014-2999(01)01012-3. [PubMed] [CrossRef] [Google Scholar]

171. Marinelli S., Di Marzo V., Berretta N., et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. The Journal of Neuroscience. 2003; 23 (8):3136–3144. [PMC free article] [PubMed] [Google Scholar]

172. Smith P. B., Compton D. R., Welch S. P., Razdan R. K., Mechoulam R., Martin B. R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. Journal of Pharmacology and Experimental Therapeutics. 1994; 270 (1):219–227. [PubMed] [Google Scholar]

173. Fride E., Mechoulam R. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent. European Journal of Pharmacology. 1993; 231 (2):313–314. doi: 10.1016/0014-2999(93)90468-W. [PubMed] [CrossRef] [Google Scholar]

174. De Lago E., Fernández-Ruiz J., Ortega-Gutiérrez S., Viso A., López-Rodríguez M. L., Ramos J. A. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. European Journal of Pharmacology. 2002; 449 (1-2):99–103. doi: 10.1016/S0014-2999(02)01996-9. [PubMed] [CrossRef] [Google Scholar]

175. Ueda N., Puffenbarger R. A., Yamamoto S., Deutsch D. G. The fatty acid amide hydrolase (FAAH) Chemistry and Physics of Lipids. 2000; 108 (1-2):107–121. doi: 10.1016/S0009-3084(00)00190-0. [PubMed] [CrossRef] [Google Scholar]

176. Maccarrone M. Fatty acid amide hydrolase: a potential target for next generation therapeutics. Current Pharmaceutical Design. 2006; 12 (6):759–772. doi: 10.2174/138161206775474279. [PubMed] [CrossRef] [Google Scholar]

177. Di Marzo V., Maccarrone M. FAAH and anandamide: is 2-AG really the odd one out? Trends in Pharmacological Sciences. 2008; 29 (5):229–233. doi: 10.1016/j.tips.2008.03.001. [PubMed] [CrossRef] [Google Scholar]

178. Johnston T. H., Huot P., Fox S. H., et al. Fatty Acid Amide Hydrolase (FAAH) inhibition reduces L-3,4- dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-lesioned non-human primate model of Parkinson’s disease. Journal of Pharmacology and Experimental Therapeutics. 2011; 336 (2):423–430. doi: 10.1124/jpet.110.169532. [PubMed] [CrossRef] [Google Scholar]

179. Celorrio M., Fernández-Suáreza D., Rojo-Bustamantea E., et al. Fatty acid amide hydrolase inhibition for the symptomatic relief of Parkinson’s disease. Brain, Behavior, and Immunity. 2016; 57 :94–105. doi: 10.1016/j.bbi.2016.06.010. [PubMed] [CrossRef] [Google Scholar]

180. Hodaie M., Neimat J. S., Lozano A. M. The dopaminergic nigrostriatal system and Parkinson’s disease: molecular events in development, disease, and cell death, and new therapeutic strategies. Neurosurgery. 2007; 60 (1):17–28. doi: 10.1227/01.neu.0000249209.11967.cb. [PubMed] [CrossRef] [Google Scholar]

181. Sayd A., Antón M., Alén F., et al. Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats. International Journal of Neuropsychopharmacology. 2015; 18 (6):1–14. doi: 10.1093/ijnp/pyu111. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

182. Lastres-Becker I., Molina-Holgado F., Ramos J. A., Mechoulam R., Fernández-Ruiz J. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson’s disease. Neurobiology of Disease. 2005; 19 (1-2):96–107. doi: 10.1016/j.nbd.2004.11.009. [PubMed] [CrossRef] [Google Scholar]

183. More S. V., Kumar H., Kim I. S., Song S.-Y., Choi D.-K. Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson’s disease. Mediators of Inflammation. 2013; 2013 :12. doi: 10.1155/2013/952375. 952375 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

184. García-Arencibia M., Ferraro L., Tanganelli S., Fernández-Ruiz J. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats. Neuroscience Letters. 2008; 438 (1):10–13. doi: 10.1016/j.neulet.2008.04.041. [PubMed] [CrossRef] [Google Scholar]

185. Huang P., Liu-Chen L.-Y., Unterwald E. M., Cowan A. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice. Neuroscience Letters. 2009; 465 (1):66–70. doi: 10.1016/j.neulet.2009.08.073. [PubMed] [CrossRef] [Google Scholar]

186. González S., Scorticati C., García-Arencibia M., de Miguel R., Ramos J. A., Fernández-Ruiz J. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson’s disease. Brain Research. 2006; 1073-1074 (1):209–219. doi: 10.1016/j.brainres.2005.12.014. [PubMed] [CrossRef] [Google Scholar]

187. Fernandez-Espejo E., Caraballo I., de Fonseca F. R., et al. Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism. Neurobiology of Disease. 2005; 18 (3):591–601. doi: 10.1016/j.nbd.2004.10.015. [PubMed] [CrossRef] [Google Scholar]

188. El Banoua F., Caraballo I., Flores J. A., Galan-Rodriguez B., Fernandez-Espejo E. Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson’s model. Neurobiology of Disease. 2004; 16 (2):377–385. doi: 10.1016/j.nbd.2004.03.002. [PubMed] [CrossRef] [Google Scholar]

189. Cao X., Liang L., Hadcock J. R., et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics. 2007; 323 (1):318–326. doi: 10.1124/jpet.107.125666. [PubMed] [CrossRef] [Google Scholar]

190. Papa S. M. The cannabinoid system in Parkinson’s disease: multiple targets to motor effects. Experimental Neurology. 2008; 211 (2):334–338. doi: 10.1016/j.expneurol.2008.03.009. [PubMed] [CrossRef] [Google Scholar]

191. García-Arencibia M., González S., de Lago E., Ramos J. A., Mechoulam R., Fernández-Ruiz J. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson’s disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Research. 2007; 1134 (1):162–170. doi: 10.1016/j.brainres.2006.11.063. [PubMed] [CrossRef] [Google Scholar]

192. Fernández-Ruiz J., Moreno-Martet M., Rodríguez-Cueto C., et al. Prospects for cannabinoid therapies in basal ganglia disorders. British Journal of Pharmacology. 2011; 163 (7):1365–1378. doi: 10.1111/bph.2011.163. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

193. Gowers W. A Manual of Diseases of the Nervous System. Philadelphia, Pa, USA: P. Blakiston’s Son & Co; 1888. [Google Scholar]

194. Müller-Vahl K. R. Treatment of Tourette syndrome with cannabinoids. Behavioural Neurology. 2013; 27 (1):119–124. doi: 10.3233/BEN-120276. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

195. Müller-Vahl K. R., Schneider U., Prevedel H., et al. Δ9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. Journal of Clinical Psychiatry. 2003; 64 (4):459–465. doi: 10.4088/jcp.v64n0417. [PubMed] [CrossRef] [Google Scholar]

196. Müller-Vahl K. R., Schneider U., Koblenz A., et al. Treatment of Tourette’s syndrome with Δ 9 -tetrahydrocannabinol (THC): a randomized crossover trial. Pharmacopsychiatry. 2002; 35 (2):57–61. doi: 10.1055/s-2002-25028. [PubMed] [CrossRef] [Google Scholar]

197. Muller-Vahl K. R., Kolbe H., Schneider U., Emrich H. M. Cannabis in movement disorders. Forschende Komplementarmedizin. 1999; 6 (3):23–27. [PubMed] [Google Scholar]

198. Müller-Vahl K. R., Schneider U., Emrich H. M. Nabilone increases choreatic movements in Huntington’s disease. Movement Disorders. 1999; 14 (6):1038–1040. [PubMed] [Google Scholar]

199. Müller-Vahl K. R., Kolbe H., Schneider U., Emrich H. M. Cannabinoids: possible role in patho-physiology and therapy of Gilles de la Tourette syndrome. Acta Psychiatrica Scandinavica. 1998; 98 (6):502–506. doi: 10.1111/j.1600-0447.1998.tb10127.x. [PubMed] [CrossRef] [Google Scholar]

200. Consroe P., Sandyk R., Snider S. R. Open label evaluation of cannabidiol in dystonic movement disorders. International Journal of Neuroscience. 1986; 30 (4):277–282. doi: 10.3109/00207458608985678. [PubMed] [CrossRef] [Google Scholar]

201. Sandyk R., Snider S. R., Consroe P., Elias S. M. Cannabidiol in dystonic movement disorders. Psychiatry Research. 1986; 18 (3):p. 291. doi: 10.1016/0165-1781(86)90117-4. [PubMed] [CrossRef] [Google Scholar]

202. Venderova K., Ruzicka E., Vorisek V., Visnovsky P. Survey on cannabis use in Parkinson’s disease: subjective improvement of motor symptoms. Movement Disorders. 2004; 19 (9):1102–1106. doi: 10.1002/mds.20111. [PubMed] [CrossRef] [Google Scholar]

203. Lotan I., Treves T., Roditi Y., Djaldetti R. Medical marijuana (cannabis) treatment for motor and non-motor symptoms in Parkinson’s disease. An open-label observational study. Movement Disorders. 2013; 28 (1):p. 448. [Google Scholar]

204. Frankel J. P., Hughes A., Lees A. A. J., Stern G. M. Marijuana for parkinsonian tremor. Journal of Neurology, Neurosurgery & Psychiatry. 1990; 53 (5):p. 436. [PMC free article] [PubMed] [Google Scholar]

205. Carroll C. B., Bain P. G., Teare L., Liu X., Joint C., Wroath C. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology. 2004; 63 :1245–1250. [PubMed] [Google Scholar]

206. Snider S. R., Consroe P. Beneficial and adverse effects of cannabidiol in a Parkinson patient with sinemet-induced dystonic dyskinesia. Neurology. 1985; 35, article 201 [Google Scholar]

207. Sieradzan K. A., Fox S. H., Dick J., Brotchie J. M. The effects of the cannabinoid receptor agonist nabilone on L-DOPA induced dyskinesia in patients with idiopathic Parkinson’s disease. Movement Disorders. 1998; 13 (supplement 2):p. 29. [Google Scholar]

208. Sieradzan K. A., Fox S. H., Hill M., Dick J. P. R., Crossman A. R., Brotchie J. M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson’s disease: A Pilot Study. Neurology. 2001; 57 (11):2108–2111. doi: 10.1212/wnl.57.11.2108. [PubMed] [CrossRef] [Google Scholar]

209. Consroe P. Brain cannabinoid systems as targets for the therapy of neurological disorders. Neurobiology of Disease. 1998; 5 (6):534–551. doi: 10.1006/nbdi.1998.0220. [PubMed] [CrossRef] [Google Scholar]

210. Mesnage V., Houeto J. L., Bonnet A. M., et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clinical Neuropharmacology. 2004; 27 (3):108–110. doi: 10.1097/00002826-200405000-00003. [PubMed] [CrossRef] [Google Scholar]

211. Koppel B. S., Brust J. C. M., Fife T., et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014; 82 (17):1556–1563. doi: 10.1212/wnl.0000000000000363. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

212. Chatterjee A., Almahrezi A., Ware M., Fitzcharles M. A. A dramatic response to inhaled cannabis in a woman with central thalamic pain and dystonia. Journal of Pain and Symptom Management. 2002; 24 (1):4–6. doi: 10.1016/s0885-3924(02)00426-8. [PubMed] [CrossRef] [Google Scholar]

213. Marsden C. D. Treatment of torsion dystonia. In: Barbeau A., editor. Disorders of Movement, Current Status of Modern Therapy. Vol. 8. Philadelphia, Pa, USA: Lippincott Williams & Wilkins; 1981. pp. 81–104. [Google Scholar]

214. Uribe Roca M. C., Micheli F., Viotti R. Cannabis sativa and dystonia secondary to Wilson’s disease. Movement Disorders. 2005; 20 (1):113–115. doi: 10.1002/mds.20268. [PubMed] [CrossRef] [Google Scholar]

215. Snider S. R., Consroe P. Treatment of Meige’s syndrome with cannabidiol. Neurology. 1984; 34, article 147 [Google Scholar]

216. Lorenz R. On the application of cannabis in paediatrics and epileptology. Neuroendocrinology Letters. 2004; 25 (1-2):40–44. [PubMed] [Google Scholar]

217. Curtis A., Mitchell I., Patel S., Ives N., Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Movement Disorders. 2009; 24 (15):2254–2259. doi: 10.1002/mds.22809. [PubMed] [CrossRef] [Google Scholar]

218. Armstrong M. J., Miyasaki J. M. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2012; 79 (6):597–603. doi: 10.1212/wnl.0b013e318263c443. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

219. Sandyk R., Consroe P., Stern L., Snider S. R., Bliklen D. Preliminary trial of cannabidiol in Huntington’s disease. In: Chesher G., Consroe P., Musty R., editors. Marijuana: An International Research Report. Canberra, Australia: Australian Government Publishing Service; 1988. [Google Scholar]

220. Consroe P., Laguna J., Allender J., et al. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacology, Biochemistry and Behavior. 1991; 40 (3):701–708. doi: 10.1016/0091-3057(91)90386-g. [PubMed] [CrossRef] [Google Scholar]

221. Kogan N. M., Mechoulam R. Cannabinoids in health and disease. Dialogues in Clinical Neuroscience. 2007; 9 (4):413–430. [PMC free article] [PubMed] [Google Scholar]

222. Sandyk R., Awerbuch G. Marijuana and tourette’s syndrome. Journal of Clinical Psychopharmacology. 1988; 8 (6):444–445. doi: 10.1097/00004714-198812000-00021. [PubMed] [CrossRef] [Google Scholar]

223. Hemming M., Yellowlees P. M. Effective treatment of Tourette’s syndrome with marijuana. Journal of Psychopharmacology. 1993; 7 (4):389–391. doi: 10.1177/026988119300700411. [PubMed] [CrossRef] [Google Scholar]

224. Hasan A., Rothenberger A., Münchau A., Wobrock T., Falkai P., Roessner V. Oral Δ9-tetrahydrocannabinol improved refractory Gilles de la Tourette syndrome in an adolescent by increasing intracortical inhibition: a case report. Journal of Clinical Psychopharmacology. 2010; 30 (2):190–192. doi: 10.1097/jcp.0b013e3181d236ec. [PubMed] [CrossRef] [Google Scholar]

225. Brunnauer A., Segmiller F. M., Volkamer T., Laux G., Müller N., Dehning S. Cannabinoids improve driving ability in a Tourette’s patient. Psychiatry Research. 2011; 190 (2-3):p. 382. doi: 10.1016/j.psychres.2011.05.033. [PubMed] [CrossRef] [Google Scholar]

226. Berding G., Müller-Vahl K., Schneider U., et al. [ 123 I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Δ 9 -tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in Tourette patients. Biological Psychiatry. 2004; 55 (9):904–915. doi: 10.1016/j.biopsych.2004.01.005. [PubMed] [CrossRef] [Google Scholar]

227. Ševčík J., Mašek K. Potential role of cannabinoids in Parkinson’s disease. Drugs and Aging. 2000; 16 (6):391–395. doi: 10.2165/00002512-200016060-00001. [PubMed] [CrossRef] [Google Scholar]

228. Pan H., Mukhopadhyay P., Rajesh M., et al. Cannabidiol attenuates cisplatin-Lnduced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. Journal of Pharmacology and Experimental Therapeutics. 2009; 328 (3):708–714. doi: 10.1124/jpet.108.147181. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

229. Hernandes M. S., Café-Mendes C. C., Britto L. R. G. NADPH oxidase and the degeneration of dopaminergic neurons in Parkinsonian mice. Oxidative Medicine and Cellular Longevity. 2013; 2013 :13. doi: 10.1155/2013/157857. 157857 [PMC free article] [PubMed] [CrossRef] [Google Scholar]

230. Hebert-Chatelain E., Reguero L., Puente N., et al. Cannabinoid control of brain bioenergetics: exploring the subcellular localization of the CB1 receptor. Molecular Metabolism. 2014; 3 (4):495–504. doi: 10.1016/j.molmet.2014.03.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

231. Yamaori S., Ebisawa J., Okushima Y., Yamamoto I., Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sciences. 2011; 88 (15-16):730–736. doi: 10.1016/j.lfs.2011.02.017. [PubMed] [CrossRef] [Google Scholar]

232. Hampson A. J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (−)Δ 9 -tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95 (14):8268–8273. doi: 10.1073/pnas.95.14.8268. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

233. Bénard G., Massa F., Puente N., et al. Mitochondrial CB1 receptors regulate neuronal energy metabolism. Nature Neuroscience. 2012; 15 (4):558–564. doi: 10.1038/nn.3053. [PubMed] [CrossRef] [Google Scholar]

234. Amor S., Puentes F., Baker D., Van Der Valk P. Inflammation in neurodegenerative diseases. Immunology. 2010; 129 (2):154–169. doi: 10.1111/j.1365-2567.2009.03225.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

235. Amor S., Peferoen L. A. N., Vogel D. Y. S., et al. Inflammation in neurodegenerative diseases—an update. Immunology. 2014; 142 (2):151–166. doi: 10.1111/imm.12233. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

236. Clark L. F., Kodadek T. The immune system and neuroinflammation as potential sources of blood-based biomarkers for Alzheimer’s disease, Parkinson’s disease, and huntington’s disease. ACS Chemical Neuroscience. 2016; 7 (5):520–527. doi: 10.1021/acschemneuro.6b00042. [PubMed] [CrossRef] [Google Scholar]

237. Mena M. A., García De Yébenes J. Glial cells as players in parkinsonism: the ‘good,’ the ‘bad,’ and the ‘mysterious’ glia. Neuroscientist. 2008; 14 (6):544–560. doi: 10.1177/1073858408322839. [PubMed] [CrossRef] [Google Scholar]

238. McGeer P. L., McGeer E. G. Glial reactions in Parkinson’s disease. Movement Disorders. 2008; 23 (4):474–483. doi: 10.1002/mds.21751. [PubMed] [CrossRef] [Google Scholar]

239. Stella N. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 2010; 58 (9):1017–1030. doi: 10.1002/glia.20983. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

240. Klegeris A., Bissonnette C. J., McGeer P. L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology. 2003; 139 (4):775–786. doi: 10.1038/sj.bjp.0705304. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

241. Esposito G., Scuderi C., Savani C., et al. Cannabidiol in vivo blunts β-amyloid induced neuroinflammation by suppressing IL-1β and iNOS expression. British Journal of Pharmacology. 2007; 151 (8):1272–1279. doi: 10.1038/sj.bjp.0707337. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

242. Watzl B., Scuderi P., Watson R. R. Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Advances in Experimental Medicine and Biology. 1991; 288 :63–70. doi: 10.1007/978-1-4684-5925-8_7. [PubMed] [CrossRef] [Google Scholar]

243. Srivastava M. D., Srivastava B. I. S., Brouhard B. Δ9 Tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology. 1998; 40 (3):179–185. doi: 10.1016/S0162-3109(98)00041-1. [PubMed] [CrossRef] [Google Scholar]

244. Malfait A. M., Gallily R., Sumariwalla P. F., et al. The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proceedings of the National Academy of Sciences of the United States of America. 2000; 97 (17):9561–9566. doi: 10.1073/pnas.160105897. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

245. Mechoulam R., Parker L. A., Gallily R. Cannabidiol: an overview of some pharmacological aspects. Journal of Clinical Pharmacology. 2002; 42 (11):11S–19S. [PubMed] [Google Scholar]

246. Mechoulam R., Peters M., Murillo-Rodriguez E., Hanuš L. O. Cannabidiol—recent advances. Chemistry and Biodiversity. 2007; 4 (8):1678–1692. doi: 10.1002/cbdv.200790147. [PubMed] [CrossRef] [Google Scholar]

247. Costa B., Colleoni M., Conti S., et al. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naunyn-Schmiedeberg’s Archives of Pharmacology. 2004; 369 (3):294–299. doi: 10.1007/s00210-004-0871-3. [PubMed] [CrossRef] [Google Scholar]

248. Costa B., Trovato A. E., Comelli F., Giagnoni G., Colleoni M. The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain. European Journal of Pharmacology. 2007; 556 (1–3):75–83. doi: 10.1016/j.ejphar.2006.11.006. [PubMed] [CrossRef] [Google Scholar]

249. Assaf F., Fishbein M., Gafni M., Keren O., Sarne Y. Pre- and post-conditioning treatment with an ultra-low dose of Δ 9 -tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage. Behavioural Brain Research. 2011; 220 (1):194–201. doi: 10.1016/j.bbr.2011.02.005. [PubMed] [CrossRef] [Google Scholar]

250. Szmitko P. E., Verma S. Does cannabis hold the key to treating cardiometabolic disease? Nature Clinical Practice Cardiovascular Medicine. 2006; 3 (3):116–117. doi: 10.1038/ncpcardio0504. [PubMed] [CrossRef] [Google Scholar]

251. Fishbein-Kaminietsky M., Gafni M., Sarne Y. Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage. Journal of Neuroscience Research. 2014; 92 (12):1669–1677. doi: 10.1002/jnr.23452. [PubMed] [CrossRef] [Google Scholar]

252. Sagredo O., García-Arencibia M., de Lago E., Finetti S., Decio A., Fernández-Ruiz J. Cannabinoids and neuroprotection in basal ganglia disorders. Molecular Neurobiology. 2007; 36 (1):82–91. doi: 10.1007/s12035-007-0004-3. [PubMed] [CrossRef] [Google Scholar]

253. Price D. A., Martinez A. A., Seillier A., et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. European Journal of Neuroscience. 2009; 29 (11):2177–2186. doi: 10.1111/j.1460-9568.2009.06764.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

254. Martínez-Orgado J., Fernández-López D., Lizasoain I., Romero J. The seek of neuroprotection: introducing cannabinoids. Recent Patents on CNS Drug Discovery. 2007; 2 (2):131–139. doi: 10.2174/157488907780832724. [PubMed] [CrossRef] [Google Scholar]

255. Romero J., Martínez-Orgado J. Cannabinoids and neurodegenerative diseases. CNS and Neurological Disorders—Drug Targets. 2009; 8 (6):440–450. doi: 10.2174/187152709789824589. [PubMed] [CrossRef] [Google Scholar]

256. Beal M. F. Excitotoxicity and nitric oxide in Parkinson’s disease pathogenesis. Annals of Neurology. 1998; 44 (3):S110–S114. doi: 10.1002/ana.410440716. [PubMed] [CrossRef] [Google Scholar]

257. Valdeolivas S., Satta V., Pertwee R. G., Fernández-Ruiz J., Sagredo O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: role of CB1 and CB2 receptors. ACS Chemical Neuroscience. 2012; 3 (5):400–406. doi: 10.1021/cn200114w. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

258. Zeissler M., Hanemann C., Zajicek J., Carroll C. FAAH inhibition is protective in a cell culture model of Parkinson’s disease. Journal of Neurology, Neurosurgery & Psychiatry. 2012; 83, supplement 2 :p. A15. doi: 10.1136/jnnp-2012-304200a.56. [CrossRef] [Google Scholar]

259. Sophie M., Ford B. Management of pain in Parkinson’s disease. CNS Drugs. 2012; 26 (11):937–948. doi: 10.1007/s40263-012-0005-2. [PubMed] [CrossRef] [Google Scholar]

260. Silva E. G., Viana M. A., Quagliato E. M. Diagnostic of parkinsonian syndrome in a Brazilian movement disorders clinic. Revista Neurociências. 2005; 13 (4):173–177. [Google Scholar]

261. Tinazzi M., Del Vesco C., Fincati E., et al. Pain and motor complications in Parkinson’s disease. Journal of Neurology, Neurosurgery and Psychiatry. 2006; 77 (7):822–825. doi: 10.1136/jnnp.2005.079053. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

262. Sage J. I. Pain in Parkinson’s disease. Current Treatment Options in Neurology. 2004; 6 (3):191–200. doi: 10.1007/s11940-004-0011-x. [PubMed] [CrossRef] [Google Scholar]

263. Dworkin R. H., Nagasako E. M., Galer B. S., Hetzel R. D., Farrar J. T. Assessment of pain and pain-related quality of life in clinical trials. In: Turk D. C., Melzack R., editors. Handbook of Pain Assessment. 2nd. New York, NY, USA: Guilford; 2001. pp. 519–548. [Google Scholar]

264. Dworkin R. H., Backonja M., Rowbotham M. C., et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Archives of Neurology. 2003; 60 (11):1524–1534. doi: 10.1001/archneur.60.11.1524. [PubMed] [CrossRef] [Google Scholar]

265. Dworkin R. H., Corbin A. E., Young J. P., Jr., et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology. 2003; 60 (8):1274–1283. doi: 10.1212/01.wnl.0000055433.55136.55. [PubMed] [CrossRef] [Google Scholar]

266. Greenbaum L., Tegeder I., Barhum Y., Melamed E., Roditi Y., Djaldetti R. Contribution of genetic variants to pain susceptibility in Parkinson disease. European Journal of Pain. 2012; 16 (9):1243–1250. doi: 10.1002/j.1532-2149.2012.00134.x. [PubMed] [CrossRef] [Google Scholar]

267. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 1998; 394 (6690):277–281. doi: 10.1038/28393. [PubMed] [CrossRef] [Google Scholar]

268. Ellis R. J., Toperoff W., Vaida F., et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34 (3):672–680. doi: 10.1038/npp.2008.120. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

269. Wilsey B., Marcotte T., Tsodikov A., et al. A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. Journal of Pain. 2008; 9 (6):506–521. doi: 10.1016/j.jpain.2007.12.010. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

270. Abrams D. I., Jay C. A., Shade S. B., et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007; 68 (7):515–521. doi: 10.1212/01.wnl.0000253187.66183.9c. [PubMed] [CrossRef] [Google Scholar]

271. Berman J. S., Symonds C., Birch R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial. Pain. 2004; 112 (3):299–306. doi: 10.1016/j.pain.2004.09.013. [PubMed] [CrossRef] [Google Scholar]

272. Svendsen K. B., Jensen T. S., Bach F. W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. British Medical Journal. 2004; 329 (7460):253–257. doi: 10.1136/bmj.38149.566979.AE. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

273. Rog D. J., Nurmikko T. J., Friede T., Young C. A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology. 2005; 65 (6):812–819. doi: 10.1212/01.wnl.0000176753.45410.8b. [PubMed] [CrossRef] [Google Scholar]

274. Nurmikko T. J., Serpell M. G., Hoggart B., Toomey P. J., Morlion B. J., Haines D. Sativex successfully treats neuropathic pain characterised by allodynia: a randomised, double-blind, placebo-controlled clinical trial. Pain. 2007; 133 (1–3):210–220. doi: 10.1016/j.pain.2007.08.028. [PubMed] [CrossRef] [Google Scholar]

275. Hill K. P. Medical marijuana for treatment of chronic pain and other medical and psychiatric problems: a clinical review. The Journal of the American Medical Association. 2015; 313 (24):2474–2483. doi: 10.1001/jama.2015.6199. [PubMed] [CrossRef] [Google Scholar]

276. Lynch M. E., Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. British Journal of Clinical Pharmacology. 2011; 72 (5):735–744. doi: 10.1111/j.1365-2125.2011.03970.x. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

277. Martín Fontelles M. I., Goicoechea García C. Role of cannabinoids in the management of neuropathic pain. CNS Drugs. 2008; 22 (8):645–653. doi: 10.2165/00023210-200822080-00003. [PubMed] [CrossRef] [Google Scholar]

278. Iskedjian M., Bereza B., Gordon A., Piwko C., Einarson T. R. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Current Medical Research and Opinion. 2007; 23 (1):17–24. doi: 10.1185/030079906X158066. [PubMed] [CrossRef] [Google Scholar]

279. Corey S. Recent developments in the therapeutic potential of cannabinoids. Puerto Rico Health Sciences Journal. 2005; 24 (1):19–26. [PubMed] [Google Scholar]

280. Smith P. F. Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Current Opinion in Investigational Drugs. 2002; 3 (6):859–864. [PubMed] [Google Scholar]

281. Campbell F. A., Tramèr M. R., Carroll D., Reynolds D. J. M., Moore R. A., McQuay H. J. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. British Medical Journal. 2001; 323 (7303):13–16. doi: 10.1136/bmj.323.7303.13. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

282. Hoogendijk W. J. G., Sommer I. E. C., Tissingh G., Deeg D. J. H., Wolters E. C. Depression in Parkinson’s disease: the impact of symptom overlap on prevalence. Psychosomatics. 1998; 39 (5):416–421. doi: 10.1016/s0033-3182(98)71300-3. [PubMed] [CrossRef] [Google Scholar]

283. Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis, and neurochemical background. Journal of Neurology. 2001; 248 (3):III5–11. [PubMed] [Google Scholar]

See also  Using cbd oil for nausea

284. Reijnders J. S. A. M., Ehrt U., Weber W. E. J., Aarsland D., Leentjens A. F. G. A systematic review of prevalence studies of depression in Parkinson’s disease. Movement Disorders. 2008; 23 (2):183–189. doi: 10.1002/mds.21803. [PubMed] [CrossRef] [Google Scholar]

285. Schrag A., Hovris A., Morley D., Quinn N., Jahanshahi M. Caregiver-burden in parkinson’s disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism & Related Disorders. 2006; 12 (1):35–41. doi: 10.1016/j.parkreldis.2005.06.011. [PubMed] [CrossRef] [Google Scholar]

286. Schrag A. Quality of life and depression in Parkinson’s disease. Journal of the Neurological Sciences. 2006; 248 (1-2):151–157. doi: 10.1016/j.jns.2006.05.030. [PubMed] [CrossRef] [Google Scholar]

287. Reichmann H., Schneider C., Löhle M. Non-motor features of Parkinson’s disease: depression and dementia. Parkinsonism and Related Disorders. 2009; 15 (3):S87–S92. doi: 10.1016/S1353-8020(09)70789-8. [PubMed] [CrossRef] [Google Scholar]

288. Gorzalka B. B., Hill M. N. Putative role of endocannabinoid signaling in the etiology of depression and actions of antidepressants. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011; 35 (7):1575–1585. doi: 10.1016/j.pnpbp.2010.11.021. [PubMed] [CrossRef] [Google Scholar]

289. Navarro M., Hernández E., Muñoz R. M., et al. Acute administration of the CB1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. NeuroReport. 1997; 8 (2):491–496. doi: 10.1097/00001756-199701200-00023. [PubMed] [CrossRef] [Google Scholar]

290. Moreira F. A., Lutz B. The endocannabinoid system: emotion, learning and addiction. Addiction Biology. 2008; 13 (2):196–212. doi: 10.1111/j.1369-1600.2008.00104.x. [PubMed] [CrossRef] [Google Scholar]

291. Moreira F. A., Crippa J. A. S. The psychiatric side-effects of rimonabant. Revista Brasileira de Psiquiatria. 2009; 31 (2):145–153. doi: 10.1590/S1516-44462009000200012. [PubMed] [CrossRef] [Google Scholar]

292. Barrero F. J., Ampuero I., Morales B., et al. Depression in Parkinson’s disease is related to a genetic polymorphism of the cannabinoid receptor gene (CNR1) The Pharmacogenomics Journal. 2005; 5 (2):135–141. doi: 10.1038/sj.tpj.6500301. [PubMed] [CrossRef] [Google Scholar]

293. Bambico F. R., Hattan P. R., Garant J. P., Gobbi G. Effect of delta-9-tetrahydrocannabinol on behavioral despair and on pre- and postsynaptic serotonergic transmission. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2012; 38 (1):88–96. [PubMed] [Google Scholar]

294. Gobbi G., Bambico F. R., Mangieri R., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102 (51):18620–18625. doi: 10.1073/pnas.0509591102. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

295. Denson T. F., Earleywine M. Decreased depression in marijuana users. Addictive Behaviors. 2006; 31 (4):738–742. doi: 10.1016/j.addbeh.2005.05.052. [PubMed] [CrossRef] [Google Scholar]

296. Degenhardt L., Hall W., Lynskey M. Exploring the association between cannabis use and depression. Addiction. 2003; 98 (11):1493–1504. doi: 10.1046/j.1360-0443.2003.00437.x. [PubMed] [CrossRef] [Google Scholar]

297. Porter B., MacFarlane R., Walker R. The frequency and nature of sleep disorders in a community-based population of patients with Parkinson’s disease. European Journal of Neurology. 2008; 15 (1):46–50. doi: 10.1111/j.1468-1331.2007.01998.x. [PubMed] [CrossRef] [Google Scholar]

298. Videnovic A., Golombek D. Circadian and sleep disorders in Parkinson’s disease. Experimental Neurology. 2013; 243 :45–56. doi: 10.1016/j.expneurol.2012.08.018. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

299. Trotti L. M., Bliwise D. L. Treatment of the sleep disorders associated with Parkinson’s disease. Neurotherapeutics. 2014; 11 (1):68–77. doi: 10.1007/s13311-013-0236-z. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

300. Stacy M. Sleep disorders in Parkinson’s disease: epidemiology and management. Drugs and Aging. 2002; 19 (10):733–739. doi: 10.2165/00002512-200219100-00002. [PubMed] [CrossRef] [Google Scholar]

301. Russo E. B., Guy G. W., Robson P. J. Cannabis, pain, and sleep: lessons from therapeutic clinical trials of sativex, a cannabis-based medicine. Chemistry & Biodiversity. 2007; 4 (8):1729–1743. [PubMed] [Google Scholar]

Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Ying Liu

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Felecia Hart

2 Department of Clinical Pharmacy, University of Colorado School of Medicine, Aurora, Colorado, USA.

Christen Epstein

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Mary Cook

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Stefan Sillau

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Jost Klawitter

3 Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Heike Newman

4 Regulatory Compliance Office, University of Colorado, Aurora, Colorado, USA.

Cristina Sempio

3 Department of Anesthesiology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Lisa Forman

5 Department of Gastroenterology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Lauren Seeberger

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Olga Klepitskaya

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Zachrey Baud

1 Department of Neurology, University of Colorado School of Medicine, Aurora, Colorado, USA.

Jacquelyn Bainbridge

2 Department of Clinical Pharmacy, University of Colorado School of Medicine, Aurora, Colorado, USA.

* Address correspondence to: Maureen A. Leehey, MD, Department of Neurology, University of Colorado School of Medicine, 12631 E 17th Avenue, MS B185, Aurora, CO 80045, USA [email protected]

Abstract

Background: Cannabis is increasingly used in Parkinson disease (PD), despite little information regarding benefits and risks.

Objectives: To investigate the safety and tolerability of a range of doses of cannabidiol (CBD), a nonintoxicating component of cannabis, and it’s effect on common parkinsonian symptoms.

Methods: In this open-label study Coloradans with PD, substantial rest tremor, not using cannabis received plant-derived highly purified CBD (Epidiolex ® ; 100 mg/mL). CBD was titrated from 5 to 20–25 mg/kg/day and maintained for 10–15 days.

Results: Fifteen participants enrolled, two were screen failures. All 13 participants (10 male), mean (SD) age 68.15 (6.05), with 6.1 (4.0) years of PD, reported adverse events, including diarrhea (85%), somnolence (69%), fatigue (62%), weight gain (31%), dizziness (23%), abdominal pain (23%), and headache, weight loss, nausea, anorexia, and increased appetite (each 5%). Adverse events were mostly mild; none serious. Elevated liver enzymes, mostly a cholestatic pattern, occurred in five (38.5%) participants on 20–25 mg/kg/day, only one symptomatic. Three (23%) dropped out due to intolerance. Ten (eight male) that completed the study had improvement in total and motor Movement Disorder Society Unified Parkinson Disease Rating Scale scores of 7.70 (9.39, mean decrease 17.8%, p=0.012) and 6.10 (6.64, mean decrease 24.7%, p=0.004), respectively. Nighttime sleep and emotional/behavioral dyscontrol scores also improved significantly.

Conclusions: CBD, in the form of Epidiolex, may be efficacious in PD, but the relatively high dose used in this study was associated with liver enzyme elevations. Randomized controlled trials are needed to investigate various forms of cannabis in PD.

Introduction

Parkinson disease (PD) is a common neurodegenerative disorder characterized by motor symptoms of resting tremor, bradykinesia, rigidity, and impaired balance that often has nonmotor symptoms of cognitive dysfunction, anxiety, and psychosis. Since standard treatments may only partially relieve symptoms many patients are turning to complementary and alternative medications. In many states across the United States, cannabis use has been permitted medicinally and recreationally, so increasing numbers of PD patients are using formulations with a myriad of cannabinoid components. In an anonymous web-based survey, 47.8% of PD patients reported that cannabis reduced their use of prescription medication. 1 Since the major component of the cannabis plant, Δ-9 tetrahydrocannabinol (THC), is known to sometimes cause psychosis, 2–4 cognitive dysfunction, 4–6 anxiety, 7–9 and balance impairment, 10,11 it may be especially harmful in PD. Conversely, cannabidiol (CBD), the next largest cannabinoid plant constituent, may have neuroprotective, anxiolytic, and antipsychotic effects, 12 as well as relatively good tolerability; thus, it may have benefits in PD. The purpose of this study is to begin investigating the effects of cannabis in PD by focusing on the safety of a range of doses of a purified CBD formulation, Epidiolex ® . In addition, the effect of CBD on common PD symptoms was studied.

Review of the literature shows that CBD is well tolerated at doses up to 1500 mg/day, 13–15 or ∼13 mg/kg/day, and most definitively has a central nervous system effect, for example, reduction of seizures, at 25 mg/kg/day. 16 However, the literature is sparse and inconclusive, and most studies used much lower doses, usually in combination with THC, and have shown a range of effects. A study in Huntington’s disease using purified CBD at 10 mg/kg/day showed no effect. 17 Thus, we designed this study to evaluate doses ranging from 5 to 25 mg/kg/day.

The U.S. governmental policies at the time this study was conducted required that human interventional cannabis research uses a study drug that is obtained from the National Institute on Drug Abuse (NIDA) or another Drug Enforcement Administration (DEA)-registered source. NIDA did not have a cannabis product with the desired dose of CBD that also had low enough THC content. Thus a highly purified form of CBD with minimal THC content was used for this study that was obtained from a DEA approved source.

Methods

Study participants

The trial was conducted at the University of Colorado Movement Disorders Center, an academic, tertiary referral center. Participants were eligible if they were 45–78 years old; lived in Colorado; met U.K. PD Society Brain Bank Clinical Diagnostic Criteria for idiopathic PD; and had resting tremor with at least an amplitude of ≥1 cm, that is, score of ≥2 on item 3.17 of the Movement Disorder Society Unified Parkinson Disease Rating Scale (MDS-UPDRS), in any limb while taking their usual PD medication, that is, while in the ON state. Participants had to agree not to operate a motor vehicle while taking the study drug, as required by the FDA. Key exclusion criteria included the following: cannabis detectable at the screening visit or THC detectable at the baseline visit; history of drug or alcohol dependence; use of dopamine antagonists within 180 days; and currently taking specified medications that are known to increase the risk of hepatotoxicity.

Written informed consent was obtained from all participants. This study is registered with ClinicalTrials.gov, > NCT02818777, and approved by the Colorado Multiple Institutional Review Board. Study progress and safety were monitored by its Colorado Clinical & Translational Sciences Institute Drug Safety and Monitoring Board.

Study design and procedures

Participants in this open label, dose escalation study had a screening visit, a baseline visit within 3 weeks, a final assessment visit on their maximal dose, and a safety visit 2 weeks later. From the baseline visit, qualified study participants took a pharmaceutical formulation of highly purified CBD derived from Cannabis sativa L. plant in oral sesame oil solution (100 mg/mL, Epidiolex in the United States; GW Research Ltd., Cambridge, United Kingdom) with ≤0.15% THC twice daily. CBD was started at 5 mg/kg/day and was titrated by adjusting the dose every ≥4th day, by up to 5 mg/kg/day, until the maximum targeted (20–25 mg/kg/day) or tolerated dose was achieved. Participants maintained their maximal dose, as tolerated, for 10–15 days, and then stopped it the next day. A registered nurse or nurse practitioner interviewed participants using a standardized phone script at each dose regarding study drug effects and at 3 days after stopping CBD to check for signs of withdrawal. At study visits, efficacy assessments were conducted when the participants’ PD medications were in optimal effect, that is, when participants were in their ON state. To monitor study drug compliance, participants filled out home diaries and study drug bottles were weighed. Participants maintained the same PD medications throughout the study period.

Dopaminergic medications were converted into levodopa equivalents (LE), according to the accepted formula 18 (LE=immediate-release levodopa × 1 + controlled-release levodopa × 0.75 + pramipexole × 100 + ropinirole × 20 + rotigotine × 30 + selegiline × 10).

CBD analysis

Cannabinoid concentrations were measured in plasma samples collected during the screening visit, baseline visit (before the first dose was administered), at final assessment visit (3 h after the maximal dose was administered), and at the safety follow-up visit. A previously validated high-performance liquid chromatography atmospheric pressure chemical ionization mass spectrometry-based assay determined cannabinoid levels. 19

Outcomes

The primary outcome was safety and tolerability of CBD and was measured in four ways: (1) the frequency and severity of adverse effects, using Common Terminology Criteria for Adverse Events terminology and grading, at each dose level; (2) vital signs, orthostatic blood pressures, physical examinations, electrocardiograms, and laboratory values (hematology, complete metabolic liver function tests, and urinalysis); (3) standardized assessment tools on relevant symptoms of PD; and (4) the proportion of participants that dropped out of the study due to study drug intolerance.

The prespecified major secondary outcome was the effect of CBD on severity and duration of tremor: the change from baseline to the maximal dose in the total of scores on items 3.17 and 3.18 in part III of the MDS-UPDRS in the ON state if the participant was taking anti-PD medication. Item 3.17 measures rest tremor amplitude, ranging from 0 (no tremor) to 4 (>10 cm in maximal amplitude) for each extremity and ranging from 0 (no tremor) to 4 (>3 cm in maximal amplitude) for lips/jaw. Item 3.18 measures constancy of rest tremor, ranging from 0 (no tremor) to 4 (present >75% of the examination). Other secondary outcomes were other motor signs and the common nonmotor symptoms of PD. The other motor signs were evaluated with the MDS-UPDRS parts II, III, and IV, as well as the Unified Dyskinesia Rating Scale (UDysRS). The effect of CBD on common nonmotor symptoms was measured using the following tools: MDS-UPDRS part I, Montreal Cognitive Assessment (MoCA), parts of Quality of Life in Neurological Disorders (Neurol-QOL) short forms for anxiety, depression, and emotional and behavioral dyscontrol, the Neuropsychiatric Inventory Questionnaire (NPI, © JL Cummings, 1994), Scales for Outcomes in PD-Sleep Scale (SCOPA-Sleep), 20 Fatigue Severity Scale (FSS, © Lauren B. Knupps), the Patient Reported Outcome Measurement Information System (PROMIS) pain intensity and pain interference short forms, Impulsive-Compulsive disorders in Parkinson’s disease Rating Scale (QUIP-RS), the Columbia-Suicide Severity Rating Scale (C-SSRS), 21 International Restless Legs Syndrome Study Group Rating Scale (IRLS), 22 and REM (rapid eye movement) sleep behavior disorder screening questionnaire (RBDSQ). 23

Statistical analysis

Proportions presented for each adverse event type are the number of patients with any instance of the event divided by the total number of patients. Mean severity and standard deviation were calculated by averaging all the severity scores for each adverse event type across all the occurrences of the event within each patient and then taking the mean and standard deviation of the patient means, weighted by number of events. The same procedure was performed on any event type and by dose for any event type and several of the most common adverse event types. Generalized estimating equations (GEE) logistic regression models and Cochran-Mantel-Haenszel statistics were used to investigate the effect of dosage on the odds of adverse events.

Pre–Post changes in the motor and nonmotor scores were analyzed by performing permutation paired t-tests, with a univariate alpha=0.05 considered statistically significant. The Benjamini–Hochberg procedure was considered to control the false discovery rate (FDR) at alpha=0.05.

Findings

Participant characteristics

Between October 17, 2016 and June 19, 2017, 15 participants were enrolled, one was a screen failure due to electrocardiogram changes, one withdrew consent before starting treatment, thus 13 started study drug. Safety data are presented on these 13 participants. Three dropped out due to treatment related adverse events, thus 10 completed the study. Efficacy data are presented on these 10 participants. Note that these 10 participants are also in the Safety Group. Baseline characteristics of the 13 participants that took at least 1 dose of study drug, the Safety Group, and of the 10 participants, the Efficacy Group, that finished the study are described in Table 1 .

Table 1.

Characteristics of the Participants at Baseline

Safety analysis group (n=13) Efficacy analysis group a (n=10)
Age, years, mean (SD) 68.1 (6.05) 68.7 (6.65)
Male, n (%) 10 (77) 8 (80)
Total MDS-UPDRS score, mean (SD) 39.2 (13.3) 43.2 (12.2)
Motor MDS-UPDRS score, mean (SD) 22.9 (9.3) 24.7 (8.9)
Disease duration, years, mean (SD) 6.1 (4.0) 6.3 (4.5)
H&Y, mean (SD) 1.73 (0.56) 1.75 (0.59)
MoCA, mean (SD) 28.2 (1.6) 27.9 (1.6)
Levodopa daily dose equivalent, b mean (SD) 398.3 (331.0) 443.8 (349.0)

a The 10 participants in the Efficacy Analysis Group are a subgroup of the 13 in the Safety Analysis Group. These are the 10 participants that completed the study.

b Levodopa Daily Dose Equivalent (LE)=immediate release levodopa × 1 + controlled release levodopa × 0.75 + Pramipexole × 100 + Ropinirole × 20 + Rotigotine × 30 + Selegiline × 10.

H&Y, Hoehn and Yahr scale; MDS-UPDRS, Movement Disorder Society Unified Parkinson Disease Rating Scale; MoCA, Montreal Cognitive Assessment.

Safety and tolerability

Due to adverse events experienced by the first five enrolled participants, the maximal targeted dose was reduced from 25 to 20 mg/kg/day. The mean maximum CBD dose was 19.4 (SD 5.2) mg/kg/day, that is, 1623.0 mg/day (range 552.5–3458.8 mg/day) in the safety analysis group and 20.3 (3.4) mg/kg/day in the efficacy analysis group, that is, 1731.4 mg/day (range 1014.0–3458.8 mg/day). The mean maximum volume of sesame oil taken per participant per day was 16 mL (range 5.5–34.5 mL) in the safety analysis group. The average length of time on study drug was 26.8 (8.0) days in safety group and 28.5 (3.4) days in efficacy group.

Adverse events, shown in Table 2 , reported in all participants, were transient and mild (1.17±0.49) on average. The adverse events reported at each dose are shown in Figure 1 . There were no serious adverse events and no withdrawal symptoms. The percentage of participants reporting diarrhea directly correlated with dosage, as shown in Figure 1 . A GEE logistic regression model found that each 5 mg increase in the dosage increased the odds of diarrhea by an estimated factor of 2.32 (95% CI: 1.46–3.69, p=0.01).

Adverse event frequency by dosage.

Table 2.

Adverse Effects Reported in Safety Group Analysis (n=13)

Adverse effects a Frequency, n (%) Severity, mean (SD)
Any 13 (100) 1.17 (0.49)
Diarrhea 11 (84.6) 1.24 (0.68)
Somnolence 9 (69.2) 1.10 (0.31)
Fatigue 8 (61.5) 1.17 (0.22)
Weight gain 4 (30.8) 1.17 (0.33)
Abdominal pain 3 (23.1) 1 (0)
Dizziness 3 (23.1) 1 (0)
Weight loss, nausea, anorexia, increased appetite, headache b 2 (15.4) N=6 (46.2%) 1.29 (0.37)
Vomiting, flatulence, gastroesophageal reflux disease, allergic reaction, spasm, fever, weakness b 1 (7.7) N=6 (46.2%) 1.13 (0.27)

a Adverse effects terminology and severity is as per the Common Terminology Criteria for Adverse Events. Regarding severity, 1=mild, 2=moderate, 3=severe.

b Individually each of the miscellaneous conditions occurs in only one or two patients, but when pooled for calculating the severity, 6 patients experience at least one.

There were no clinically significant adverse changes in other outcome safety assessments, except for increases in liver enzymes, especially alkaline phosphatase. Liver enzymes were measured at baseline and not again until the final assessment visit when participants were on their highest tolerated or the targeted dose. Elevations, shown in Table 3 , occurred in five (38.5%) participants, one symptomatic and four asymptomatic, all on 20–25 mg/kg/day. The symptomatic participant, ID 02, developed moderate anorexia, diarrhea, somnolence, mild abdominal pain, dizziness, fatigue, fever, headache, and weight loss; had a cholestatic pattern of liver enzyme changes; and his liver ultrasound was normal. All symptoms and laboratory changes resolved after discontinuation of study drug.

Table 3.

Liver Function Test, Final Dose, and Medications

ID Age Sex ALT (normal 7–52 U/L) BL, final, SF AST (normal 12–39 U/L) BL, final, SF GGT (normal 9–64 U/L) BL, final, SF ALP (normal 39–117 U/L) BL, final, SF, FU T. Bili (normal 0.1–1.3 mg/dL) BL, final, SF Final dose, mg/kg/day Medications known to cause ANY hepatotoxicity a Other medications
02 b 70 M 11, 150, 49 16, 58, 23 9, 206, 116 99, 503, 247, 103 0.9, 1.4, 1.0 25 Aspirin, celecoxib, rasagiline None
06 b 71 M 36, 64, 34 27, 46, 25 49, 101, 75 54, 81, 60 1.3, 1.8, 1.2 25 Acetaminophen, fish oil, lisinopril, rasagiline, sildenafil, vitamin B6 Biofreeze, glucosamine chondroitin, loperamide, magnesium, potassium citrate, vitamin B12, vitamin D3
08 b 70 M 12, 41, 9 17, 80, 29 29, 229, 229 12, 317, 182, 94 0.7, 0.9, 0.4 20 Acetaminophen, aspirin, atorvastatin, doxazosin, esomeprazole, meloxicam Carbidopa/levodopa, finasteride
09 b 68 M 13, 29, 11 19, 22, 16 46, 129, 68 108, 137, 107 0.7, 0.7, 0.4 20 Aspirin, ibuprofen, lisinopril, methylphenidate, ropinirole, selegiline, trazodone Melatonin, vitamin D3
10 b 68 M 16, 20, 12 15, 30, 18 20, 162, 62 75, 134, 84 0.6, 0.6, 0.6 20 Amantadine, aspirin, atorvastatin, citalopram, ibuprofen, omeprazole, Ropinirole Carbidopa/levodopa, coQ10, folic acid, melatonin, vitamin C
01 68 F 4, 8, N/A 17, 20, N/A N/A, 13, N/A 62, 53, N/A 0.4, 0.4, N/A 17.5 Escitalopram, fish oil, gabapentin, lansoprazole, lorazepam, ropinirole, prasterone Carbidopa/levodopa, CoQ10, garlic, magnesium, melatonin, MiraLAX ® , nystatin, senna, turmeric, vitamin B complex, vitamin D2
03 75 M 13, 14, N/A 15, 19, N/A 17, 16, N/A 33, 31, N/A 0.8, 1, N/A 25 Amlodipine, aspirin, hydrochlorothiazide, metoprolol, telmisartan Docusate, calcium, etanercept, magnesium, vitamin B12
04 74 M 3, 8, N/A 17, 25, N/A 20, 24, N/A 38, 38, N/A 0.4, 0.5, N/A 25 Diclofenac, hydrochlorothiazide, docosahexaenoic acid, propranolol, selegiline Carbidopa/levodopa, coQ 10, Heart Burn Relief ® , multivitamin, stool softener.
05 62 M 25, 25, N/A 21, 29, N/A 54, 51, N/A 53, 49, N/A 1, 0.8, N/A 5 Fish oil, ibuprofen (Advil ® ), meloxicam, olmesartan, rasagiline Albuterol, coQ10, fluticasone, melatonin.
07 74 M 3, 4, N/A 19, 17, N/A 13, 11, N/A 54, 49, N/A 0.5, 0.7, N/A 20 Aspirin, clonazepam, entacapone, loratadine, omeprazole, simvastatin, tramadol Carbidopa/levodopa, Centrum ® , ocuvite, omega 3, pramipexole, vitamin D3
11 58 F 20, 26, N/A 18, 18, N/A 15, 20, N/A 57, 63, N/A 0.5, 0.4, N/A 20 Estradiol, lisinopril, prasterone, progesterone, rasagiline CoQ10, magnesium, melatonin, pramipexole
13 73 M 25, 37, N/A 26, 42, N/A 24, 56, N/A 52, 64, N/A 0.7, 0.7, N/A 12.5 Acetaminophen, gabapentin, Ibuprofen, niacin/chromium Carbidopa/levodopa, coQ10, ferrous sulfate
14 56 F 4, 6, N/A 19, 20, N/A 11, 14, N/A 80, 84, N/A 0.4, 0.4, N/A 20 Conjugated estrogens, naproxen, nortriptyline, sumatriptan Bone Nutrient ® , carbidopa/levodopa, cellular vitality, diphenhydramine, essential oil, Food Nutrient ®

ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; BL, baseline visit; final, final visit; FU, follow-up visit, participants had ALP checked until it was in the normal range; GGT, gamma-glutamyl transferase; M, male; mg/dL, milligrams per deciliter; SF, safety follow-up visit 2 weeks after final visit; T. Bili, total bilirubin; U/L, units per liter.

Three participants (23%) stopped study drug due to intolerability, one due to rash at 5 mg/kg/day, one to abdominal pain and gas at 17.5 mg/kg/day, and one, described above, to fatigue, diarrhea, and elevated liver enzymes, that is, hepatitis, at 25 mg/kg/day.

Efficacy

The mean decreases in the total and motor MDS-UPDRS scores at the maximal dose compared with baseline were a 17.8% (p=0.012) and 24.7% (p=0.004) improvement, respectively. Two nonmotor assessments also showed significant improvement, the SCOPA-Sleep nighttime and the emotional and behavioral dyscontrol short form. At 2 weeks follow-up, the total MDS-UPDRS and nighttime sleep assessments remained improved; the other two assessments did not. Enrolled subjects had minimal levodopa induced dyskinesia, cognitive dysfunction, restless leg syndrome symptoms, REM sleep behavior disorder, and impulsivity at baseline, and these assessments did not change on study drug. Table 4 shows the data for all assessments.

Table 4.

Change in Motor and Nonmotor Scores Among Efficacy Analysis Group (n=10)

Baseline, mean (SD) Final, mean (SD) Change from baseline to final, mean (SD) p a Follow-up, mean (SD) Change from baseline to follow-up, mean (SD) p a
Rest Tremor b 3.10 (2.23) 2.70 (2.31) −0.40 (1.26) 0.471 4.20 (2.10) 1.10 (2.56) 0.109
Total MDS-UPDRS 43.20 (12.21) 35.50 (14.31) −7.70 (9.39) 0.012 a 35.70 (14.97) −7.50 (6.74) 0.008 a
Motor MDS-UPDRS 24.70 (8.93) 18.60 (9.66) −6.10 (6.64) 0.004 a 27.40 (10.51) 2.70 (4.74) 0.188
H&Y 1.75 (0.59) 1.80 (0.89) 0.05 (0.76) 1.000 1.95 (0.685) N/A N/A
SCOPA-Sleep NS 5.70 (2.95) 2.90 (2.60) −2.80 (3.91) 0.040 a 3.30 (2.36) −2.40 (3.66) 0.023 a
SCOPA-Sleep DS 2.60 (2.27) 2.20 (1.69) −0.40 (1.65) 0.575 2.10 (2.42) −0.50 (1.84) 0.453
Emotional and behavioral dyscontrol SF 44.39 (7.91) 39.70 (6.75) −4.69 (6.14) 0.047 a 40.17 (7.08) −4.22 (7.24) 0.125
NPI 0.78 (1.20) 0.75 (1.39) −0.13 (1.55) 1.000 N/A N/A N/A
Anxiety SF 46.24 (6.35) 46.57 (7.27) 0.33 (3.57) 0.783 45.99 (7.05) −0.25 (4.11) 0.945
Depression SF 43.09 (6.03) 42.24 (7.04) −0.85 (3.13) 0.440 41.1 (5.85) −1.99 (4.55) 0.500
Fatigue Severity Scale 28.50 (15.54) 28.00 (14.49) −0.50 (11.46) 0.907 27.4 (14.91) −1.10 (9.85) 0.648
Pain interference SF 52.25 (8.63) 49.93 (8.99) −2.320 (6.008) 0.253 49.94 (9.16) −2.31 (6.99) 0.438
Pain intensity SF 44.64 (7.36) 42.78 (9.20) −1.860 (4.711) 0.311 42.96 (9.78) −1.68 (5.20) 0.469

a Paired t-test, permutation distribution; p-values of less than 0.05 were considered to indicate statistical significance.

b Rest tremor score was the prespecified major secondary outcome: total of the severity (MDS-UPDRS item 3.17) and duration (MDS-UPDRS item 3.18) of rest tremor.

NPI, Neuropsychiatric Inventory Questionnaire; SCOPA-Sleep DS, Scales for Outcomes in Parkinson’s Disease-Sleep, Daytime Sleep; SCOPA-Sleep NS, Scales for Outcomes in Parkinson’s Disease-Sleep, Nighttime Sleep; SD, standard deviation; SF, Short Form.

Applying the Benjamini–Hochberg procedure to control the FDR at alpha=0.05 found none of the tests to be statistically significant. The small sample size severely limits power for multiple testing adjustment.

CBD plasma levels

Three hours after the final dose was administered, the participant on 12.5 mg/kg/day had a CBD plasma level of 181 ng/mL, while those on 20 mg/kg/day, n=7, showed plasma levels of 376±78 ng/mL (mean±SEM) and those on 25 mg/kg/day, n=2, showed plasma levels of 340±4 ng/mL. Fourteen days after discontinuation of CBD, the values were 13, 24±5, and 39±14 ng/mL for the 12.5, 20, and 25 mg/kg/day treatment groups, respectively.

Discussion

In this study five participants (38%) had transient elevated liver enzymes, one symptomatic and four asymptomatic, resolving after discontinuation of the study drug. In this study, the pattern of enzyme changes, particularly in the symptomatic patient, was consistent with a cholestatic rather than hepatocellular process. The drug may have caused idiopathic or bland cholestasis and, much less likely, granulomatous hepatitis or vanishing bile duct syndrome, since all liver tests normalized. Liver biopsy was not performed. None of these participants had significant elevated bilirubin or internalized normalized ratio, suggesting no change in liver function.

While liver enzyme elevations in a hepatocellular pattern have been reported with Epidiolex 16 on doses similar to those taken by the present study participants, the cholestatic pattern has not. Single or multiple factors, such as older age, having PD, concomitant medications, and relatively high CBD dosage, may contribute to this. To date Epidiolex has been used primarily in pediatric populations. Perhaps older age and/or pathologic mechanisms that underlie PD, for example, mitochondrial dysfunction, are relevant factors. Regarding concomitant medications, most of the participants in prior epilepsy studies on Epidiolex were also on valproate; and while none in this PD study was, they were taking concomitant medications with potential hepatotoxicity, as shown in Table 3 . Generally medications specific for PD have little potential for hepatotoxicity, with the exception of tolcapone, which none of the study participants was taking. There was no apparent diffence in the overall hepatotoxic potential of concomitant medications being taken by those that did and did not develop liver enzyme changes. Table 3 also shows the final CBD dose of participants, and again there was no apparent difference between those that did and did not have liver enzyme changes. Thus, it is unlikely that the liver enzyme elevations were solely due to hepatotoxicity of concomitant medications or CBD dose. Regarding dose, in this study liver enzymes were tested at the final, that is, highest dose, and not at lower doses, so the dose at which liver enzymes started to change is unknown. Perhaps persons with PD would have better tolerability of lower doses. Taken in whole, it is likely that multiple factors contributed to the liver enzyme changes that occurred in this study, with older age and relatively high CBD dosage being particularly relevant.

This was an open label study so no conclusions can be drawn regarding efficacy. However, assessments were done to check for hints of efficacy to inform future studies. The results suggest that CBD has a beneficial effect on total and motor MDS-UPDRS scores, nighttime sleep, and emotional and behavioral dyscontrol. Interestingly, the p-values on these assessments were still significantly or close to significantly improved 2 weeks after stopping CBD, compared to baseline. It is possible that CBD was still having some effect, since participants still had low plasma levels at that time.

A review of the literature of clinical studies of cannabinoids in PD shows that four randomized, blinded controlled studies have been reported, one Class 1 25 (according to the American Academy of Neurology Classification of Evidence for Rating of a Therapeutic Article, © 2014 American Academy of Neurology, AAN.com/guidelines), one Class 2, 26 and two Class 3. 27,28 Other studies were open label, 29–31 case reports, 32,33 or surveys. 34–36 These other studies mostly evaluated cannabis; one included CBD, 25 and three studied 99% pure CBD. 26,29,32

The presented study is the first study of the effects of relatively high dose, ∼20 mg/kg/day, purified CBD in humans with PD. There were three prior studies of purified oral CBD, with reports of effects of lower doses. A double-blind study in 21 participants using ∼4.5 mg/kg/day found no change in UPDRS and other outcomes, except improved scores on the PD Questionnaire-39, which assessed functioning and well-being. 26 An open label study in six patients found an improvement in total UPDRS scores and psychotic symptoms on ∼5 mg/kg/day of pure oral CBD. 29 The third study was open label and reported that four participants taking ∼1–4 mg/kg/day had improvement in REM sleep behavior disorder, that is, reduction in acting out dreams. 32 These three studies reported no adverse events. Other studies in PD examined the use of cannabis: two measuring the acute effects of smoked cannabis, total n=42, reported significantly improved motor UPDRS scores and reduced pain, 30,31 another administered a medium dose of oral THC (0.25 mg/kg/day) and very low dose of CBD (0.125 mg/kg/day), n=17, and showed no significant change on all measured outcomes. 25 Adverse effects of cannabis included somnolence, dizziness, decreased concentration, palpitations, and altered taste. Accumulating literature suggests that CBD may reduce psychosis, 29,37 which is a frequent debilitating symptom in PD.

Most previous pre-clinical studies using animal models of PD have focused on cannabinoid receptor 1 (CB1) agonists and antagonists, rather than pure CBD. The studies show evidence of therapeutic effects, improving motor symptoms, and levodopa induced involuntary movements, that is, dyskinesia. However, these effects were found with both CB1 agonists and antagonists. Furthermore, there is a dose dependent effect: low doses of CB1 antagonists have been reported to improve motor function and dyskinesia more consistently than CB1 agonists, while high doses of both CB1 agonists and antagonists have no effects or impair motor function. 38–47 Regarding CBD, a study using the 6-hydroxydopamine rat model of PD found that CBD, and also THC, attenuated neurodegeneration from the toxin, perhaps through antioxidant or anti-inflammatory mechanisms. 48 Another study with the same toxin inducing PD, but in mice, studied pain thresholds and suggested that CBD modulated analgesic effects by increasing anandamide, a major endocannabinoid, levels and acting on CB1 and the transient receptor potential vanilloid receptor 1 (TRPV1) and that lower doses are more effective than intermediate doses. 49 Evidence from pre-clinical studies to date suggests that there is more to learn about the effects of different types of cannabinoids on the motor signs of PD. 38–47,50–54

How CBD influences PD is unclear, as its effect in humans is complex. CBD has low affinity for the endogenous cannabinoid receptors, but it can upregulate the levels of anandamide, by inactivation of fatty acid amide hydrolase, which metabolizes anandamide. Equally important, CBD interacts with many noncannabinoid signaling systems, and these functions may vary depending on its concentration. 55 Activation of the serotonin 5-HT1A receptor may underlie improvement of motor signs. 56 Other theories involve actions at G-protein coupled receptor 55, 57,58 TRPV1, 59,60 and GRP6 receptors. For example, the G-coupled protein receptor GPR6 is highly expressed in the basal ganglia. Depletion of GPR6 causes an increase of dopamine. By acting as an inverse agonist at the GPR6 receptor, CBD boosts dopamine levels in pre-clinical studies. 61 A neuroprotective effect has been proposed due to studies showing anti-oxidant activity, for example, upregulating superoxide dismutase mRNA levels in the substantia nigra, 62–65 and through anti-inflammatory activity, for example, activating peroxisome proliferator-activated receptor gamma. 62,66–69

The plasma concentrations of CBD in our participants were consistent with prior pharmacokinetic studies of Epidiolex. Taylor et al. 70 showed in a multiple ascending dose study of Epidiolex at 750 mg and 1500 mg twice daily (21.4 and 42.8 mg/kg/day for a 70 kg person) a tmax of ∼3–5 h after administration, depending on fasting versus nonfasting state. The Cmax was also dependent on the fasting state: 335 ng/mL when subjects were fasting versus 1628 ng/mL when subjects received a high-fat breakfast. In our study CBD plasma peak concentrations 3 h after the last administration of study drug of the treatment period (10–15 days) were 376±78 ng/mL (mean±SEM) for the 20 mg/kg/day (n=7). This is consistent with the Epidiolex PK study 70 where 290 ng/mL (in the morning, fasting) and 732 ng/mL (in the afternoon, not fasting) were reported in the 750 mg (∼21 mg/kg/day) twice daily group. However, relatively high interindividual variabilities were observed in our study, likely because we did not control for food intake.

This study has some limitations. First, conclusions about adverse effects, but especially efficacy, are limited by the absence of a placebo arm. Also rater bias can occur in an open label design, both with regard to noting adverse effects, as well as rating scale assessments. Note, however, that the data that showed improved sleep and emotional and behavior dyscontrol were collected from participant questionnaires, rather than a rater. Furthermore, the number of participants was small and those included had minimal dyskinesia, cognitive dysfunction, restless leg syndrome, REM sleep behavior disorder, and impulse control disorder. These important problems may be altered by CBD treatment, but they were not addressed in this study. Furthermore, efficacy did not achieve significance when adjusted for multiple testing.

There was not a significant change in the major secondary outcome, tremor. Tremor was chosen because of the author’s clinical experience: persons with PD in clinic frequently reported reduction in tremor with CBD, but rarely reported changes in other motor symptoms. Participants had to have a tremor amplitude in the ON state of at least 2 cm to be in the study, but tremor is variable from time to time and thus may be a less reliable motor symptom to measure. Quantifying tremor at home with a device may yield a more accurate measurement.

Further study of the effects of cannabinoids in PD is greatly needed, since presently these persons are trying products with various cannabinoid compositions despite little data regarding safety and efficacy. The usual dose of CBD in dispensary products is quite variable, for example, 2–200 mg/day, is much lower than that used in this study, and the CBD is often combined with clinically relevant doses of THC. Besides dosage, routes of administration might alter outcomes, for example, smoking or vaping would likely cause more immediate intense and shorter lasting effects. As increasing numbers of persons with PD visit cannabis dispensaries, they are presented with a wide range of choices. Randomized controlled studies are needed to confirm this study’s findings and to investigate lower doses of CBD, CBD in combination with THC at varying compositions, and the effects of routes of administration.

Acknowledgments

The authors are grateful to Emil Diguilio, Sarah Fischer, and Candace Ellman for their assistance in preparation of this article, to Nicole Gendelman and the University of Colorado Department of Neurology Core Clinical Trials Team for their help with all aspects of conducting this study, and especially thank the patients that participated in this study.